Studies of the Protein Kinases of alpha-Herpes Viruses by Stevens, Rowena
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Studies of the
VrAcinlfcm\*cz cf 
ce-Herpce \I\r\x*e*
Submitted for the degree of Ph.D 
by Rowena Stevens
November 1989 
Department of Biochemistry 
University of Glasgow
©  Rowena Stevens 1989.
ProQuest Number: 11003326
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 11003326
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
ACKNOWLEDGEMENTS
I am very grateful to Dr David P. Leader for taking me on as a 
PhD student at such short notice and would like to express my sincere 
thanks to him for his continual support, help and encouragement 
throughout the two years.
I would like to thank Professor M. D. Houslay for making the 
facilities of the department available to me.
I am also glad to acknowledge the assistance bf Dr. Dimetrios A. 
Spandidos of the Beatson Institute for Cancer Research, Glasgow, who 
performed the calcium phosphate transfections of recombinant plasmids 
into eukaryotic cells and the selection for geneticin resistant 
transformants, and of Dr. John Kussel who prepared the purified 
fusion-proteins for injection into rabbits.
For the photographic work in this thesis, I would like to 
express my gratitude to the photographers in Medical Ilustrations for 
taking the photographs, and to my brother, Andrew, for the loan of 
his photographic equipment and for teaching me how to print 
photographs.
I would also like to thank my friends in C36, especially Val and 
Beate, for their help and friendship throughout my time in the lab.
Finally, I am very grateful to my parents for all their support 
and encouragement.
TABLE OF CONTENTS
Page
ACKNOWLEDGEMENTS ii
TABLE OF CONTENTS ill
LIST OF FIGURES vii
LIST OF TABLES x
ABBREVIATIONS xi
SUMMARY xiv
Chapter 1
INTRODUCTION 1
A. Herpes Viruses 2
A.1 The Structure of Herpes Virions 3
A. 2 The Life Cycle and Latent Infection 3
A. 3 The Viral Genome 8
B. Protein Kinases 14
B.1 Classification of Protein Kinases 14
B.2 Sequence Motifs of Protein Kinases 15
B.3 Activities of Protein Kinases 18
B.4 Functions of Protein Kinases 19
B. 5 Protein Phosphatases 20
C. Protein Kinases and Viral Infection 23
Chapter 2
MATERIALS AND METHODS
A. Materials
1. Radiochemicals 44
2. Fine chemicals 44
3. Cell lines 48
4. Viruses 48
5. Bacteria 48
6. Plasmids 49
B. Methods
1. E. coll culture 50
1. 1 Preparation of competent cells for transformation 51
1.2 Transformation of E, coll with plasmid DNA 51
- iii—
Page
2. Preparation of plasmid DNA
2. 1 Small scale plasmid "mini-prep" 51
2.2 Large scale plasmid "mini-prep" 52
2. 3 Large scale plasmid preparation 53
3. Manipulation of DNA 54
3. 1 Restriction endonuclease digestions 55
3.2 Deproteinisation with phenol 55
3.3 Ethanol precipitation of DNA 55
3.4 Treatment of vector DNA with alkaline phosphatase 55
3.5 Ligation 56
4. Electrophoresis
4.1 Electrophoresis of DNA in agarose gels 56
a) Standard 1% agarose gel 56
b) Low melting point agarose gel 57
c) Elution of DNA from low melting point agarose gels 57
4.2 Electrophoresis of Proteins on Polyacrylamide gels 57
a) Coomassie Blue staining 58
b) Silver staining 59
c> Acetone precipitation of proteins 59
5. Cell culture 60
5.1 Storage and recovery of cells 60
5.2 Growth of cells in culture 61
5.3 Measurement of growth of 208F cells and derived 62
cell lines
6. Infection of BHK cells with PRV
6.1 Infection for preparation of virus stocks 63
6.2 Infection for preparation of purified virions 63
6.3 Infection for preparation of purified PRV-PK 63
7. Preparation and extraction of PRV virions
7.1 Preparation of PRV virions 64
7.2 Extraction of protein kinase activity from PRV virions 66
8. Assay and isolation of PRV-PK
8. 1 Protein kinase assay (using protamine as a 67
substrate)
8.2 Isolation of PRV-PK 68
a) Preparation of post-ribosomal supernatants from 68
infected and uninfected BHK cells
b) DEAE-cellulose chromatography of protein kinases 69 
in post-ribosomal supernatants from tissue
culture cells
i) Analytical chromatography
ii) Preparative chromatography
c) Hydrophobic-interaction chromatography on 69
TSK phenyl-5PW
d) Threonine-Sepharose chromatography 70
- iv -
e) Protamine-agarose chromatography
f) The specific activity of the final material from 
the purification of PRV-PK
9. Phosphorylation of viral proteins
9. 1 Phosphorylation of viral structural proteins
in vitro
a) Endogenous protein kinase activity
b) Exogenous protein kinase activity
9.2 Detection of the phosphorylation of proteins 
during infection of cells
a) Preparation of extracts from infected cells
b) Preparation of virions from the medium of 
infected cells
9.3 Preparation of autoradiographs
10. Preparation of 0-galactosidase fuslon-proteins for 
injection into rabbits for the preparation of specific 
anti-sera
10. 1 Expression of (3-galactosidase fusion-protein in
E. coli
10.2 Preparation of E. coli protein extract
10.3 Partial purification of the fusion-protein by 
Sephacryl S300 chromatography
10.4 Injection of fusion-protein into rabbits
11. Preparation of Anti-sera
11.1 Bleeding of rabbits
11.2 Preparation of anti-serum
11.3 Affinity-purification of anti-serum by elution 
from nitrocellulose filters
12. Immunoblotting
Chapter 3 
RESULTS
A. Studies with antibodies.
A. 1 Construction of recombinants for the expression of 
fusion-proteins 
A.2 Expression and partial purification of fusion-proteins
A. 3 Initial characterisation of anti-sera
B. The purification of PRV-PK and the determination of the 
relationship between this enzyme and the product of the 
pk gene of PRV.
C. Location of PRV-PK and HSV-PK within virions.
Page
71
71
72
72
72
73
74
74
75
75
75
76
77
77
77
78
81
81
83
85
87
90
- v —
Page
D. The phosphorylation of viral structural proteins of PRV 
i n  v i t r o  and i n  vivo.
E. Attempt to express the US3 gene of HSV-1 in eukaryotic cells.
E.1 Construction of the plasmids, transformation of 
recombinants into 208F cells and selection of 
transf ormants
E. 2 Attempts to detect HSV-PK and characterisation of the 
phenotype of transformant cell lines.
Chapter 4 
DISCUSSION
A. The relationship between the 38kDa protein kinase 
(PRV-PK) and the PRV pk gene.
B. Occurrence and Implications of the presence of PRV-PK 
within the virions.
94
98
99
101
135
139
REFERENCES 142
LIST OF FIGURES
Introduction
1. 1 Schematic diagram showing the arrangement of the 
genomes of HSV-1, PRV and EBV.
1.2 Schematic diagram of UQ and Rs regions from 
the genomes of PRV, HSV-1 and VZV, showing 
homologous genes.
1.3a Schematic diagram showing the Bam HI cleavage 
sites in the PRV genome
1.3b Schematic diagram of Bam HI fragments 7 
and 10 of the PRV genome.
1.4 Shared sequence motifs of the conserved subdomains 
within the catalytic domain of protein kinases
Results
3. I Schematic diagrams of the expression vector pUEX 
and the recombinants pUEX-P and pUEX-S for 
expression of protein kinase fusion-proteins.
3.2 Construction of pUEX-P and pUEX-S: Identification 
of clones with the insert in the desired 
orientation by restriction digestion with Bam HI.
3. 3 Time course of expression of (3-galactosidase and 
the HSV-1 fusion-protein in E. coli.
'3.4 Extraction of fusion-proteins from E. coli.
3.5 Partial purification of the PRV fusion-protein by 
chromatography on Sephacryl S300.
3.6 Partial purification of the HSV-1 fusion-protein 
by chromatography on Sephacryl S300.
3.7a Polyacrylamide gel electrophoresis of partially 
purified fusion-proteins. 
b Characterisation of anti-sera and pre-immune sera 
with respect to the fusion-proteins
3.8 Activity of anti-serum P towards extracts from 
uninfected cells and cells infected with PRV or 
HSV-1.
Page
30
31
32
32
33
106
107
108
109
110
111
112
112
113
-vii-
Page
3.9 Activity of anti-serum S towards extracts from 114
uninfected cells and cells infected with PRV or 
HSV-1.
3. 10 Purif icat ion of PRV-PK. 115
3. 11 Purification of PRV-PK: DEAE-cellulose column. 116
3. 12 Purif icat ion of PRV-PK: TSK phenyl-5PW column. 118
3. 13 Purification of PRV-PK: Threonine-Sepharose column. 119
3. 14 Purif icat ion of PRV-PK: Protamine-agarose column. 120
3. 15 Characterisationi of affinity-purified antibodies. 121
3.16a Protein and immunochemical analysis of PRV virions 122
and nucleocapsids. 
b Immunochemical analysis of extracts of PRV virions 122
after treatment with NP-40.
3. 17 Immunochemical analysis of HSV-1 virions using 123
anti-serum S.
3.18a The proteins phosphorylated in extracts prepared 124
from cells incubated with C32P]orthophosphate 
during infection with PRV or during mock-infection. 
b The phosphorylation of viral structural proteins 124
of PRV in vivo.
c The phosphorylation of viral structural proteins 124
of PRV in vivo.
3. 19 The phosphorylation of structural proteins of 125
heat-inactivated PRV virions by PRV-PK, 
cAMP-dependent protein kinase and casein kinase II.
3.20 The phosphorylation of nucleocapsids by endogenous 126 
and exogenous protein kinases In vitro.
3.21 The effect of heparin, polyarginine and 0.5M KC1 127 
on the phosphorylation of PRV virions by the 
endogenous protein kinase activity in vitro,
3.22 Schematic diagrams of pIC 20H and the recombinants 128 
pIC-K/S and pIC-B/S.
3.23 Schematic diagrams of Homer 5 and the recombinants 129 
H5-Kaf H5-Kb, H5-Ba and H5-Bb.
-viii-
Page
3.24 Construction of H5-Ka, H5-Kb, H5-Ba and H5-Bb: 
Confirmation of the identity of clones and 
determination of orientation by restriction 
digestion.
3.25 Analysis of protein kinase activity present in 
the cell lines 208F, Ka-2 and Kb-2.
3.26 Light microscopic appearance of the cell line 
used for transformation with Homer constructs 
and resulting geneticin resistant clones.
3.27 Cell growth curves showing the rates of growth 
and saturation density of cell lines 208F, Ka-2 
and Kb-2.
3.28 Cell growth curves showing the rates of growth of 
the cell lines 208F, Ka-2 and Kb-2 in the presence 
and absence of geneticin.
130
131
132
133
134
- ix-
LIST OF TABLES
Introduction Page
I Immediate-early proteins of HSV-1 34
II Glycoproteins of HSV-1 34
III Proteins of HSV-1 essential and sufficient for 34
DNA replication
IV Other enzymes encoded by the genome of HSV-1 35
V Genes encoding virion proteins of HSV-1 35
VI Eukaryotic serine/threonine protein kinases 36
having narrow substrate specificities
VII Eukaryotic serine/threonine protein kinases 37
having broad substrate specificities
VIII Protein kinases known to undergo 38 
autophosphorylation
IX Protein kinases involved in the regulation of 40
cell growth
X Functions of eukaryotic serine/threonine protein 41
kinases
XI Characteristics of protein phosphatases 43
-X
ABBREVIATIONS
The abbreviations recommended by the Biochemical Journal in its 
instructions to authors (Blochem. J. 241 1-17) have been used with 
the following additions:
anti-serum P anti-serum raised against protein product of part 
of pk gene
anti-serum S anti-serum raised against protein product of part
of US3 gene 
BHK baby kidney hamster (cells)
BSS balanced salt solution
CaM calmodulin
C-terminus Carboxy-terrainus (of protein)
D-MEM Dulbecco modified Eagle's minimum essential
medium
DMSO dimethyl sulphoxide
DTT dithiothreitol
EBV Epstein-Barr virus
EF-2 elongation factor-2
EGF epidermal growth factor
elF elongation initiation factor
EHV-1 equine herpes virus type 1
ES Earle's salts
G-MEM Glasgow modification of Eagle's minimum essential
medium
- xi -
gp glycoprotein
HMCV human cytomegalovirus
HMG CoA hydroxymethylglutaryl CoA
HPLC high pressure liquid chromatography
HSV-1 herpes simplex virus type 1
HSV-2 herpes simplex virus type 2
HSV-PK protein kinase induced during infection with HSV-1
IE immediate early (gene)
IPTG isopropyl-thiogalactoside
MAP-2 microtubule associated protein-2
MEM minimum essential medium
NP-40 Nonidet P-40
OD optical density
oz ounce
PBS phosphate buffered saline
pfu plaque forming units
PK protein kinase
PMSF phenylmethylsulphonyl fluoride
PP protein phosphatase
PRV pseudorabies virus
PRV-PK protein kinase induced during infection with PRV
Ru long repeat (region of genome)
Rs short repeat (region of genome)
TBE Tris, Borate, EDTA (buffer)
TE Tris, EDTA (buffer)
TEA Tetraethylaramonia
TEMED N, N, N' , N-tetramethyl-ethylene diamine
- x i i -
TPA 12-0-tetra-decanoyl phorbol-13-acetate
Ul unique long (region of genome)
Us unique short (region of genome)
VSV vesicular stomatitis virus
VZV varidella zoster virus
X-gal 5-bromo-4-chloro-3-indolyl-0-galactoside
SUMMARY
This work concerns the two similar protein kinase activities - 
HSV-PK and PRV-PK - which are found in cultured animal cells 
infected with herpes simplex virus type 1 (HSV-1) and pseudorabies 
virus (PRV), respectively; and two genes, predicted from their 
sequence to encode protein kinases: US3 in HSV-1 and pk in PRV. The 
aims of this work were to determine the relationship between pk and
PRV-PK, and to investigate the location and possible substrates of
the protein kinases.
First, anti-sera were raised against the protein products of the 
US3 and pk genes in the form of fusion-proteins with 0-galactosidase 
in E. coll. A 0. 8kb Sal I fragment of the US3 gene and a 0.8kb Pst I 
fragment of the pk gene were separately cloned into appropriate sites 
in the p-galactosidase gene of the plasmid vector pUEX-2, and E. coll 
cells were transformed with the resulting recombinants. The 
fusion-proteins were induced, partially purified by gel exclusion 
chromatography, injected into rabbits and anti-sera were prepared.
PRV-PK was purified to homogeneity by successive chromatography
on DEAE-cellulose, TSK phenyl-5PW, threonine-Sepharose and protamine-
agarose. During the purification, protein kinase activity coeluted
with material of 38kDa, found only in infected cells, which showed
immunoreactivity towards the anti-serum raised against the protein
product of the pk gene of PRV. This demonstrated that PRV-PK is
encoded by the pk gene of PRV, and is consistent with previous work
which had indicated that the US3 gene of HSV-1 encodes HSV-PK. This
anti-serum also cross-reacted with a cellular protein of 34kDa which
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was resolved from PRV-PK during chromatography on DEAE-cellulose. As 
a result of this cross-reactivity, the anti-serum was unsuitable for 
immunochemical studies which might have determined the location of 
the enzyme within intact infected cells.
The anti-sera were used to investigate the location of PRV-PK 
and HSV-PK within their respective virions. Purified virions were 
subjected to polyacrylamide gel electrophoresis and the proteins 
transferred to nitrocellulose. The anti-serum raised against the 
product of the US3 gene reacted with two proteins of 68kDa and 69kDa, 
as was also observed for extracts from infected cells. This 
indicated that HSV-PK is present within the virions of HSV. The 
anti-serum raised against the product of the gene, pk, reacted with a 
single protein of 38kDa, demonstrating that PRV-PK is present within 
the virions of P1V. This anti-serum also reacted with purified 
nucleocapsids and with virions which had been treated with the 
non-ionic detergent, NP-40, to remove the envelope of the virion.
This implies that PRV-PK is associated with the nucleocapsid, which 
may be important in determining the physiological substrateCs) of the 
viral kinase.
Possible viral substrates of PRV-PK within PRV virions were 
investigated. Purified virions were incubated with yl3^PlATP, 
subjected to gel electrophoresis and the phosphorylated proteins 
detected by autoradiography. The major phosphorylated protein had a 
molecular weight of 112000. This protein was also phosphorylated 
when virions, in which the endogenous protein kinases had been 
inactivated by heat, were incubated with exogenous PRV-PK in the 
presence of y[3aP]lATP, demonstrating that the 112kDa protein can be
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a substrate for PRV-PK in vitro. When cells were incubated with 
C32P]orthophosphate during infection in vivo, the 112kDa protein was
also phosphorylated. This suggested that the 112kDa protein may be
a physiological substrate of PRV-PK. However, at least three other 
distinct protein kinases have been identified in PRV virions, one of 
which, casein kinase II, can also phosphorylate this virion protein 
in vitro. When PRV virions were incubated with y^32P^ATP in the 
presence of 0. 5M KC1, which inhibits casein kinase II but not PRV-PK, 
the phosphorylation of the 112kDa protein was inhibited. This
implies that casein kinase II is responsible for most of the
phosphorylation of the 112kDa protein in isolated virions in vitro, 
but does not exclude the possibility that the protein is a substrate 
for PRV-PK in vivo. However, immunochemical assays showed that PRV- 
PK is at least 100 times more abundant in the cytosol of infected 
cells than within virions, so that it seems more likely that the 
physiological role of PRV-PK involves the phosphorylation of proteins 
within the cytosol of infected cells.
An attempt was made to detect possible cellular substrates for 
HSV-PK by expressing the US3 gene constitutively in eukaryotic cells, 
after introducing it into the cellular genome. A 2.8kb fragment of
v
DNA which included the promoter and coding region for US3 was cloned
into the vector, Homer 5. The recombinants were transformed into
208F rat fibroblasts by calcium phosphate precipitation, and
transformants selected by resistance to geneticin, which was
conferred by the vector. Extracts from the transformed cell lines
were subjected to chromatography on DEAE-cellulose and assayed for
HSV-PK activity, but this could not be detected. Cell lines
-xvi-
expressing greater quantities of HSV-PK will be required before this 
approach to identify a possible cellular substrate can be executed.
-xvii-
Chapt er 1 
INTRODUCTION
This work concerns two related protein kinases: those encoded by 
the genome of the herpes viruses, Herpes Simplex Virus 1 (HSV-1) and 
Pseudorabies Virus (PRV). The interest in these viral enzymes stems
from what is known about other protein kinases. Since cellular
protein kinases are known to be involved in the regulation of many 
cellular processes, it seems likely that a viral protein kinase may 
similarly play a regulatory role during viral infection. The 
infection of cells with herpes viruses is a system potentially well
suited to studying the effects of the activity of a particular
protein kinase, since the viral protein kinases are specifically 
induced during infection, and this process brings about many changes 
in the infected cell that might well be mediated by the viral protein 
kinase.
In this Introduction, the characteristics of herpes viruses, 
their morphology, life cycle and the structure of their genome will 
first be presented. The activities and functions of some protein 
kinases in general will then be considered before discussing in more 
detail the discovery and characterisation of the protein kinases 
induced during infection of cells with HSV-1 (HSV-PK) and PRV 
(PRV-PK).
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A. Herpes Viruses
The herpes viruses are a large group of DNA viruses which infect 
a wide range of animal hosts (Roizman & Batterson, 1985). Of 
particular interest are the five which infect humans, namely HSV-1, 
HSV-2, Varicella Zoster Virus (VZV), Epstein Barr Virus (EBV) and 
Human Cytomegalovirus (HCMV), and also those which infect domestic 
animals, e.g. PRV, which infects pigs. Herpes viruses can be 
subdivided into three groups (a, 0, y) according to their 
pathological behaviour. The a-herpes viruses, which include HSV-1, 
HSV-2, VZV and PRV, are characterised by having a variable host range 
and a relatively short reproductive cycle. Lytic infection results 
in the destruction of the infected cells. However these viruses may 
also produce latent infections in neurons. Reactivation can occur 
under conditions of stress to produce lytic infection. The {3-herpes 
viruses, in contrast, have a restricted host range and a long 
reproductive cycle. Lytic infection frequently results in the 
enlargement of the infected cells. {3-herpes viruses can also produce 
latent infections in secretory glands and kidneys. HCMV is a member 
of this group. The y-herpes viruses, of which EBV is the most 
studied example, principally infect lymphoblastoid cells and 
frequently produce latent infections.
- 2 -
A. 1 The Structure of Herpes Virions.
All herpes virions share a characteristic structure in which 
there is a core, nucleocapsid, tegument and envelope (Widly et al. , 
1960). The core consists largely of a single protein species around 
which the viral DNA is wound. This is enclosed within an icosahedral 
nucleocapsid which is formed from 162 capsomers. A number of other 
proteins, including some which have been identified as having enzymic 
activity, are also associated with the nucleocapsid. The tegument 
forms a layer of variable thickness between the nucleocapsid and the 
viral envelope, and contains most of the minor structural proteins of 
the virion. Finally, the envelope consists of a membrane acquired 
from budding through the cell's nuclear membrane. Specific viral 
glycoproteins are inserted into this membrane, at least some of which 
are known to be important in the interaction between virions and 
target cells.
A. 2 The Life Cycle and Latent Infection.
The life cycles of all a-herpes viruses appear to be similar, but 
that of HSV-1 has been studied most thoroughly. Adsorption onto the 
target cell is presumed to involve interaction between the viral 
glycoproteins and specific receptors on target cells, thus limiting 
the number of cell types which a particular virus can infect, and 
determining the host range of the virus (Vahne et al. , 1979). 
Penetration, which also involves at least one of the viral 
glycoproteins (gB in the case of HSV-1 : Sarmiento et al. , 1979), is
- 3 -
probably brought about by the fusion of the virion envelope with the 
host plasma membrane. The virion particle, lacking the envelope, is 
then transported to the nucleus where it sheds the nucleocapsid 
proteins, and the viral DNA enters the nucleus through the nuclear 
pores (Batterson et al., 1983). Certain virion proteins also enter
the nucleus, including, in HSV-1 (but not in PRV), a 65kDa protein 
required for the stimulation of transcription of viral genes 
(Batterson & Roizman, 1983; Campbell et al. , 1984; Dalrymple et al, ,
1985).
The viral genes can be divided into three groups. These are 
the immediate-early (a), early (3) and late <7) genes (Honess & 
Roizman, 1974). All the genes are transcribed by the cellular RNA 
polymerase II (Constanzo et al. , 1977), but certain viral proteins 
switch on and off the transcription of each group of genes. The a 
genes (of which there are five in HSV-1 : table I) only require the 
65kDa (UL48 or Vmw65) viral structural protein for their expression. 
Thus, they can be transcribed in the presence of cycloheximide 
(Honess & Riozman, 1974), which inhibits protein synthesis. Under 
these conditions, the transcripts of the a genes accumulate, 
suggesting that the a genes are negatively regulated by the 
translation product of one of the a genes, and this has been shown to
be a4 (IE 175, the product of the gene RSI : DeLuca et al., 1985).
This protein is also required for the expression of the 3 genes 
(Preston, 1979; Preston, 1981). This latter class of genes can be 
subdivided into two groups, 3* and 32, according to when they are 
expressed. Expression of the 31 genes occurs very early during
infection. The expression of both groups, however, reaches a maximum
- 4 -
5-7h after infection (Honess & Roizman, 1974). The products of the 
P genes include proteins involved directly or indirectly in DNA 
synthesis, eg. DNA polymerase, DNA-binding protein, thymidine kinase. 
The y genes are expressed late in infection after the initiation of 
viral DNA synthesis, which is a stringent requirement for the 
expression of the y2 genes (Conley et al., 1981). Most of the
Y genes encode structural proteins of the virion.
The viral genome is present within the virion as a linear double­
strand of DNA of 120-240kbp. On entry into the nucleus of the 
infected cell, the DNA molecule becomes circularised. Replication 
then occurs by the rolling circle method to produce concatamers which 
are cleaved during their insertion into nucleocapsids (Jacob & 
Roizman, 1977; Jacob et al. , 1979).
Assembly of the virion occurs largely within the nucleus. The 
nucleocapsid proteins, having been translated on polyribosomes 
associated with the cytoskeleton, are transported into the nucleus 
where they form capsids into which the DNA is inserted (Biber-Hardy 
et al., 1982; Ben-Ze'ev et al., 1983). Newly-synthesised viral 
glycoproteins are inserted into the nuclear membrane in regions which 
become devoid of cellular proteins. Capsids then become enveloped by 
budding through the inner nuclear membrane at regions containing the 
viral glycoproteins (Darlington & Moss, 1968; Nii et al. , 1968).
These virions probably proceed through the endoplasmic reticulum and 
then bud through this to form vesicles from which they are released 
by fusion with the plasma membrane (reverse pinocytosis). However, 
there is also evidence for the envelopment of nucleocapsids occurring 
by budding into cytoplasmic vacuoles and Golgi membranes (Smith &
- 5 -
Harvea, 1973). The importance of thia pathway is unclear, but it may 
help to account for the presence of cellular cytosolic proteins 
(eg. casein kinase II : Introduction C) within mature virions.
The processes involved in latent infection and its reactivation 
are much less well understood. For HSV-1, they have been studied 
using the infection of mice, since it does not seem possible to 
produce latency in vitro with this virus. This is in contrast to EBV 
in which latency frequently occurs on infection of B lymphocytes in 
culture. The latter allows the processes occurring at the cellular 
level to be investigated, but is complicated by the fact that the 
infected cells are also induced to replicate indefinitely. One 
explanation that has been proposed to account for the failure to 
induce latency in vitro with HSV-1 is that the immune system may be 
involved in supressing productive infection in vivo (Roizman & Sears, 
1987).
HSV-1 forms latent infections in ganglia adjacent to the sites 
of productive infection. Virions originating from lytic infection 
probably infect the nerve endings and are transported along the axon 
to the nucleus. Several hundred copies of the viral genome appear to 
be present in the nuclei of these cells, suggesting that the viral 
genome is replicated, probably by a cellular DNA polymerase. The 
viral DNA is no longer a single linear molecule (Rock & Fraser, 1983: 
Rock & Fraser, 1985), but it is unclear if it is maintained as an 
episome, as in the case of EBV, or whether it is a concatamer which 
is not integrated into the chromosome of the host cell (Mellerick & 
Fraser, 1987).
- 6 -
Two approaches have been used to try to identify the viral 
proteins involved in establishing and maintaining latency; the 
construction of mutant viruses from which one particular gene has 
been deleted, and the detection of viral genes expressed in cells 
which are harbouring latent infection. Deletion mutants lacking one 
of the following genes were still found to be able to form latent 
infections in mice (Meignier et al., 1988): US3 which encodes the 
viral protein kinase, US4 which encodes the glycoprotein gG, US8 
which encodes glycoprotein gE, US12 which encodes the a protein, a47 
(IE 12), and US2 and US11 the functions of which are unknown. This
suggests that these genes are not involved in establishing latency.
In another study (Leib et al., 1989) three deletion mutants of the
ix gene, ocO (IE 110 encoded by RL(1)), were found to be able to
replicate in ganglia, but varied in their ability to establish latent 
infection and to permit its subsequent reactivation, suggesting that 
a0 plays a role in both the establishment and reactivation of 
latency. The second approach has identified a new transcript in 
latently infected cells which has not been detected in productive 
infections (Stevens et al.t 1987; Spivack & Fraser, 1987; Wagner 
et al., 1988). It has been suggested that the transcript may not be 
translated since it is predominantly present in the nucleus. Although 
the function of the transcript is not known, these observations 
suggest that it may be involved in latency.
The switch from latency to productive infection has been studied 
for EBV since with this virus it occurs spontaneously at a low 
frequency In vitro. The expression of the gene BZLF-1 can induce 
lytic infection in 50% of cells harbouring latent infection. The
- 7 -
product of this gene is a transactivator of some EBV promoters and 
hence probably acts to induce the genes involved in lytic infection 
(Countryman & Miller, 1985; Takada et al., 1986; Chevallier-Greco et 
al., 1986; Grogan et al., 1987). This suggests that the suppression 
of the expression of BZLF-1 is involved in establishing latent 
infection. The phorbol ester, 12-0-tetra-decanoyl phorbol-13-acetate 
(TPA), is also able to activate latent infections (Faggioni et al.,
1986). This suggests that the normal inducer of reactivation to 
lytic infection in humans may be an inducer of the hydrolysis of 
phosphatidyl-inositol, for example a hormone or growth factor. It 
seems likely that the processes involved in the reactivation of 
latent infection are similar for HSV-1 and EBV, but there is much 
that is still not understood about latency and its reactivation.
A. 3 The Viral Genome.
Herpes viruses have double-stranded linear DNA genomes of 120- 
240kbp which encode about 70 or more proteins. They can be divided 
into five groups according to the structure of their genomes, which 
consist of unique and repeated sequences (Roizman, 1981). Only the 
three arrangements which are relevant to the viruses to be discussed 
here will be presented (fig 1.1). These consist of two regions 
containing unique sequences, UQ (unique short) and Uu (unique long). 
In HSV-1 and HSV-2, Ul_ is flanked by a sequence (Rl.) which is present 
in the opposite orientation at either end of Uu. Another repeated 
sequence (R©) flanks U© (Sheldrick & Berthelot, 1974; Wadsworth 
et al. , 1975). Both unique sequences together with their flanking
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repeated sequences can invert relative to each other, giving rise to 
four isomers of the genome which are present in equal frequency 
within any preparation of the virus (Hayward et al. , 1975). The
genome of VZV also has such an arrangement. In PRV, U8 is similarly 
flanked by a repeated sequence in opposite orientations, but U^. is 
only flanked by a variable number of shorter direct repeats (Stevely, 
1977; Ben-Porat et al., 1979). Only two isomers of the PRV genome 
exist since only can undergo inversion. The genome of EBV exists 
only as one isomer. A variable number of direct repeats are present 
at either end of the genome while Us and Ul_ are separated by a number 
of larger tandemly repeated sequences (Given & Kieff, 1979; Kintner & 
Sugden, 1979; Hayward et al. , 1980). Despite these differences in
the overall arrangement of the genomes, it has been found that the 
arrangement of genes within the genomes are similar, especially for 
viruses from the same group (eg. HSV-1 and VZV).
The homology between the genomes of different herpes viruses was 
initially investigated by measuring the cross-hybridisation between 
genomic DNAs. This showed that HSV-1 and HSV-2 were more closely 
related to each other than to either VZV or PRV, and that PRV and VZV 
were not closely related either (Kieff et al., 1972; Ludwig et al. , 
1972). In another study (Davison 8t Wilkie, 1983), the arrangement of 
homologous regions in different a-herpes viruses was compared by 
investigating to which restriction fragments from one viral genome, a 
particular restriction fragment from another viral genome could 
hybridise. In this way Davison & Wilkie showed that HSV-1 and HSV-2 
are col inear, that the homologous regions of equine herpes virus 
type 1 and VZV are colinear, and that PRV is colinear to a particular
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isomer CI,_) of HSV-1, except for an inversion of the region 
containing the first 40% of the genome (genome units 0. 1 to 0.4). 
These early conclusions have been substantiated and were extended by 
the comparison of genomes for which the complete nucleotide sequence 
has been determined ie. the a-herpes viruses HSV-1 (McGeoch et al. , 
1985; McGeoch et al. , 1988a) and VZV (Davison & Scott, 1986), and the
Y~herpes virus, EBV (Baer et al., 1984). These were found to consist
of 152260bp, 124884bp and 172282bp respectively.
The genome of HSV-1 encodes a total of 70 genes, of which 56 are 
in the Uu region, 12 are in the Us region, and the terminal repeated 
regions each contain one gene, both of which are therefore present 
twice within the genome (McGeoch et al. , 1988a). These latter two
genes encode the a proteins, aO (IE 110) and a4 (IE 175). All the 
genes except RL(1), UL1 and UL15 lack introns. Although all the 
genes are transcribed from one or more distinct promoter, only 29 of 
the termination sites for transcription are unique to the transcript 
of one gene. The other 19 termination sites are shared by two or 
more transcripts. Thus, many of the mRNAs encode more than one 
protein, although it is likely that only the first open reading frame 
of each transcript is translated.
Something is known about the functions of the protein products of 
about half of the genes encoded by HSV-1. These can be divided into 
a number of groups according to what is known of their properties. 
There are five a (immediate-early) genes (table I), three of which 
appear to be essential for productive infection ie. a0 (IE 110), 
a4 (IE 175) and <x27 (IE 63). These are transactivators of viral 
transcription. Seven genes encode the glycoproteins which are
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inserted into the viral envelope (table II). Another seven genes 
have been shown to be essential and sufficient for DNA replication 
(table III). These include the viral DNA polymerase, components of 
the helicase-primase complex and three DNA-binding proteins. The 
genome also encodes a number of enzymes which are involved in 
nucleotide metabolism (table IV). These are dispensable for growth 
in culture. The other enzymes which the genome is known to encode 
are an exonuclease, and a protein kinase, the product of gene US3 
(Purves et al., 1987b), which is discussed further below. From the 
sequence of UL13, it is possible that this gene encodes a second 
protein kinase (Chee et al., 1989; Smith & Smith, 1989). Two virion
regulatory proteins have been identified (table V): the protein 
product of UL41 brings about the initial inhibition of host protein 
synthesis (Kwong et al., 1988), while (JL48 encodes Vrnw65, the virion
protein which is the activator for expression of the a (immediate- 
early) genes (Batterson & Roizman, 1983; Campbell et al. , 1984; 
Dalrymple et al. , 1985). Six proteins, defined by molecular weight,
have been identified as components of the nucleocapsid. The genes 
encoding two of these have been identified (table V): UL19 encodes 
one of the major structural components (Costa et al., 1984), and UL26
encodes a surface component which may be involved in the assembly of 
virions (Davison & Scott, 1986b; Preston et al., 1983). There remain 
seven genes which are known to encode virion proteins, but which have 
not yet been correlated with the known structural proteins.
Comparison of the amino acid sequences predicted for the proteins 
encoded by the genes of the Uu region of HSV-1 with those predicted 
for VZV showed that for most of the genes in HSV-1 there is an
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equivalent gene in VZV, and that it is located at the same position 
within both genomes (McGeoch et al. , 1988a). In the Uu region, the
VZV genome was found to have five genes without equivalents in HSV-1 
ie. genes 1, 2, 13 (thymidylate synthase), 32, and 57. There are two 
genes in the Uu region of HSV-1 without equivalents in VZV ie. UL45 
and UL50. The Us region of HSV-1 contains six genes without 
equivalents in VZV ie. US2, US4, US5, US6 US11 and US12, but all the 
genes in the Us region of VZV have equivalents in HSV-1. Another 
difference is that in VZV, gene 61, the equivalent of HSV-1, 
aO (IE 110), is present within the Uu region rather than R,_ and hence 
only has one copy within the genome.
A comparison of the predicted amino acid sequences for the genes 
of VZV and EBV identified seven having strong homology, eight having 
moderate homology and 15 having weak homology (Davison & Taylor,
1987). All the homologous genes are located within the Ul. region of 
both genomes. However, the positions of the homologous genes within 
the Ul_ region are not directly equivalent, in contrast to the 
situation regarding HSV-1 and VZV. The Uu region can be divided into 
three sections, which are orientated ABC in VZV but CA'B in EBV 
(where A' is the inverse orientation of A). Thus, the Uu region of 
the Y”herpe8 virus, EBV, is more distantly related to the U,_ region 
of the a-herpes viruses than are the equivalent regions of HSV-1 and 
VZV to each other. No homology has been detected between the 
proteins encoded by the U© region of EBV and those of VZV or HSV-1, 
or indeed that of the {3-herpes virus, HMCV (Weston & Barrell, 1986).
The Us region of HSV-1 and its flanking repeated sequence 
contains 13 distinct open reading frames (fig 1.2) (McGeoch et al. ,
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1985). The corresponding region of VZV contains seven distinct 
genes, all of which have counterparts in HSV-1 (Davison & Scott,
1986). With the exception of US1, these genes are located in the 
same order in the two viruses.
Part of the Us region of PRV has been sequenced. Most of the Us 
region lies within the Bam HI-7 fragment of the genome (fig 1.3). 
This was found to contain five open reading frames which encode four 
glycoproteins: gX (Rea et al., 1985), gp50 (Petrovskis et al. ,
1986a), gp63 (Petrovskis et al., 1986b), gl (Petrovskis et al.,
1986b) and an llkDa protein (Petrovskis & Post, 1987). The 
glycoprotein gX corresponds to glycoprotein gG in HSV-2 (encoded by 
the US4 gene), but does not show any homology to the protein encoded 
by US4 in HSV-1 (McGeoch et al., 1987). The other four proteins 
correspond to the products of US6, US7, US8 and US9 in HSV-1 
respectively (fig 1.2).
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B. Protein Kinases
Protein kinases are enzymes which catalyse the transfer of a 
phosphate group from a nucleotide, usually ATP, to the hydroxyl group 
of a seryl, threonyl or tyrosyl residue of a protein. Although 
several protein kinases are now known in prokaryotes, it is in 
eukaryotes that there appear to be a large number of different 
protein kinases. To date about one hundred different mammalian 
protein kinases have been identified, but it has been suggested that 
there may be as many as 1000 eukaryotic protein kinases (Hunter,
1987). This multiplicity appears to be a feature of eukaryotes, and 
may be highly significant in eukaryotic evolution in that the 
processes in which protein kinases are implicated, such as complex 
cell differentiation and the response to hormones, do not occur in 
prokaryotes.
B. 1 Classification of Protein Kinases.
Protein kinases differ from each other in a number of different 
properties which can be used to define and classify them. These 
include i) molecular structure, ii) substrate specificity for the 
amino acid which is phosphorylated and the range of proteins 
phosphorylated, iii) the mechanism of activation, and iv) tissue 
distribution. One classification scheme involves the division of 
protein kinases into two groups according to whether they 
phosphorylate seryl and threonyl, or tyrosyl residues, with a further
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division on the basis of their mechanism of activation eg. 
cAMP-dependent protein kinase, or their protein substrate specificity 
eg. glycogen synthase kinase 3.
B. 2 Sequence Motifs of Protein Kinases.
Most protein kinases are found to consist of at least two
domains, one of which is the catalytic domain, whereas another may be
involved in the regulation of the catalytic activity, and often binds 
an allosteric activator eg. cGMP, Ca2+. Like many other families of 
related enzymes, the amino acid sequences of protein kinases are 
found to share significant homology within their catalytic domains, 
and this presumably reflects their similar catalytic mechanisms.
This homology was first observed by Barker & Dayhoff (1982), who 
found that the amino acid sequences of the catalytic subunit of the 
cAMP-dependent protein kinase and the tyrosine protein kinase, 
pp60“v'c, shared a significant number of identical amino acids. This
was subsequently shown to be a more general phenomenon by the 
extensive homology found between the cAMP-dependent protein kinase 
and the cGMP-dependent protein kinase (Takio et al,, 1984), and
between these and the y subunit of phosphorylase b kinase (Reimann 
et al., 1984).
The amino acid sequences or predicted amino acid sequences are
now known for over fifty protein kinases. These include both
serine/threonine and tyrosine protein kinases of both vertebrate and 
invertebrate origin, some of which are homologues from different 
species. From a comparison of these sequences, Hanks et al. (1988)
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defined eleven regions of homology which are separated by regions of 
much lower homology. Six of these consist of sequences with 2-8 
amino acids which are conserved to varying degrees (fig 1.4). The 
other regions of homology consist of a single amino acid which is 
highly conserved, flanked by less highly conserved amino acids, or a 
sequence of amino acids which undergo conservative changes 
(eg. conserving their hydrophobic or hydrophilic character). The 
latter are thus more difficult to define and use as diagnostic 
sequences for identifying protein kinase genes.
The motif G-G— G-V, in subdomain I, was originally thought to be 
totally conserved, but with the sequencing of more protein kinases, 
only the second glycine residue has been found to remain totally 
conserved. A similar motif is also present in other proteins which 
bind nucleotides, including several for which the crystal structure 
has been determined (eg. adenylate kinase ; Von Zabern et al., 1976;
which has the motive G GK). From this, it is suggested that the
motif is probably located in the fold between two a-helices and is 
part of the nucleotide binding domain.
The lysine residue in subdomain II is probably present in all 
protein kinases. In chemical modification studies of several protein 
kinases with the ATP analogue, p-fluorosulphonylbenzoyl 5'-adenosine, 
the conserved lysine residue has been shown to be modified (Zoller 
et al., 1981; Hashimoto et al. , 1982). This, together with the 
observation that mutation of this residue can abolish kinase activity 
(Snyder et al., 1985; Kamps & Sefton, 1986), suggests that this 
lysine is involved in the catalytic mechanism of protein kinases.
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There are two motifs which can be of use in differentiating 
between tyrosine and serine/threonine protein kinases. Within domain 
VI there is a sequence, AAR, which, although not totally conserved, 
appears to be characteristic of tyrosine protein kinases, except 
those related to src, in which, in most cases, it is replaced by RAA. 
The equivalent sequence in serine/threonine protein kinases is 
considerably more diverse. The second motif is a sequence within 
subdomain VIII which can be diagnostic of tyrosine protein kinases:
P-(K/R)WCT/M). Although such motifs can be of use to distinguish 
between tyrosine and serine/threonine protein kinases, the overall 
homology of tyrosine protein kinases to one another is sufficiently 
great that genes encoding tyrosine protein kinases are probably most 
effectively identified by comparing the sequence of the whole 
catalytic domain to that of known tyrosine protein kinases.
The identification of these motifs from the amino acid sequences 
or the conceptual translations of the nucleotide sequences of known 
protein kinases has had considerable predictive value. A number of 
genes for which the product was unknown have been identified as 
probably encoding protein kinases on the basis of their predicted 
amino acid sequences. These include many retroviral oncogenes and 
their corresponding cellular proto-oncogenes, eg. c-mos (Van Beveren 
et al., 1981), and the products of a number of genes encoding 
regulators of the cell cycle in yeast and other eukaryotic organisms 
eg. cdc2 (Hindley & Phear, 1984), weel- (Russel & Nurse, 1987a), 
nlml+ (Russel & Nurse, 1987b). In several cases, this has been 
substantiated (eg. Simatfis & Nurse, 1986).
Of particular relevance here is the fact that this approach 
identified the QS3 gene of HSV-1 and its homologues in HSV-2 and VZV 
as putative protein kinase genes (McGeoch & Davison, 1986). The 
predicted amino acid sequences for the three proteins can be divided 
into two sections which probably reflect their functional domains.
The C-terminal domain shows about 45% identity between HSV-1 and VZV, 
except for the extreme C-terminal region, and contains sequence 
motifs characteristic of the catalytic domain of protein kinases 
(Leader & Purves, 1988). The N-terminal domain shows little apparent 
homology between HSV-1 and VZV and also varies in size between the 
different enzymes. Its purpose is thus unclear. The way in which it 
was established that the US3 gene does encode a protein kinase is 
described in a later section (Introduction C).
B. 3 The Activities of Protein kinases
The specificity of protein kinases appears to range from those 
which are highly specific, only being known to phosphorylate one or a 
few proteins (table VI), to others which have a much broader 
specificity (table VII). In the case of the latter, the specificity 
is probably largely defined by the amino acids around the serine, 
threonine or tyrosine on the target protein. Such specificities have 
been investigated using peptides as substrates, and are shown in 
table VII. Substrate recognition for protein kinases with much 
narrower substrate specificities probably depends on secondary and 
tertiary structural features of the substrate proteins as well as the 
primary structure. What proteins are phosphorylated by a particular
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protein kinase in vivo may also be determined by the localisation of 
a protein kinase to a particular tissue or subcellular compartment. 
This is thought to be important for tyrosine protein kinases.
Many protein kinases are known to undergo autophosphorylation 
(table VIII). In many cases this appears to be functionally 
significant. Autophosphorylation of many serine/threonine protein 
kinases results in activation of the protein kinase or reduces the 
dependence of the enzyme on allosteric activators. For some of the 
oncogenic tyrosine protein kinases, autophosphorylation is important 
in the activation of the protein kinase and transforming activity 
(eg. pp60“r,c : Smart et al. t 1981). However, there are other enzymes 
for which autophosphorylation appears to have no effect, and hence 
may not occur under physiological conditions (eg. casein kinase II; 
Dahmus, 1981).
B. 4 Functions of Protein Kinases.
Protein kinases are believed to play an important role in the 
regulation of many cellular processes by bringing about the 
phosphorylation of key regulatory proteins. Such processes include 
the regulation of metabolic pathways, muscle contraction, 
neurotransmitter release, protein synthesis, cell proliferation, the 
activation of cells such as platelets and mast cells, and the 
regulation of the cell cycle. The processes which are better 
understood are those involving a protein kinase for which the 
substrate(s) is known. Most of these protein kinases have a limited 
substrate specificity (table VI). However, protein kinase C has been
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implicated in a number of processes, although the substrates involved 
have not been conclusively identified (Nishizuka, 1986). Most of the 
tyrosine protein kinases and some serine protein kinases have been 
identified as proto-oncogenes (table IX). This implies that they are 
involved in the regulation of cell proliferation, but since their 
substrates have not been identified (other than the enzymes 
themselves) it is not known how they exert their effects. Some of 
these proto-oncogenes are receptors for hormones and growth factors 
eg. EGF and PDGF. The binding of the ligand activates the tyrosine 
protein kinase activity, and this has been shown in the case of the 
insulin receptor to be important for signal transduction, but how 
this is brought about is unknown (Ellis et al., 1986; Chou et al. ,
1987) .(taMeX)
B.5 Protein Phosphatases.
Although eukaryotic protein kinases thus appear to be important 
in many cellular processes, the protein phosphatases which oppose the 
actions of the protein kinases may well be equally important in 
these. Compared with protein kinases, there appear to be a more 
limited number of protein phosphatases. For serine/threonine protein 
phosphatases, four different classes of enzyme have been described, 
three of which have broad substrate specificities. The properties of 
these enzymes are shown in table XI. The broad and overlapping 
substrate specificities of PP-1, PP-2A and PP-2C make it difficult to 
determine their relative importance in the dephosphorylation and 
hence the regulation of particular substrates In vivo. However, they
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show differences in cellular location, which probably relate to 
substrate specificity (Cohen, 1988). Thus the two major active forms 
of PP-1 in muscle, PP-Iq and PP-1M, are particulate, being associated 
with glycogen and myosin, respectively. PP-la consists of the 
catalytic subunit associated with a glycogen-binding subunit 
responsible for the association of the enzyme complex with glycogen 
(Stralfors et al., 1985). A similar targeting subunit is probably
also associated with PP-1M. In contrast, PP-2A and PP-2C are mainly 
cytosolic.
PP-1 and PP-2B are known to be highly regulated in response to 
the second messengers Ca2"' and cAMP. PP-1 is inhibited by the 
inhibitor protein, inhibitor-1, which is activated by cAMP-dependent 
protein kinase (Huang & Glinsmann, 1976; Nimmo & Cohen, 1978). This 
probably serves to amplify the response to hormones such as glucagon, 
which act via the activation of protein kinases. The glycogen-binding 
subunit of PP-1Q can also be phosphorylated by cAMP-dependent protein 
kinase (Stralfors et al., 1985; Caudwell et al. , 1986), which results 
in the dissociation of PP-1Q from glycogen (Hiraga & Cohen, 1986) and 
facilitates its inactivation (Stralfors et al. , 1985). The catalytic 
subunit of PP-2B is activated by association with the 
Ca2-*--binding subunit of PP-2B, or calmodulin. Both interactions 
require Ca2*', which thus effectively regulates this enzyme. PP-2B 
has a much narrower substrate specificity than the other three 
protein phosphatases (Ingebritsen & Cohen, 1983a) and appears to be 
specific for proteins which regulate other protein phosphatases 
(eg. inhibitor-1 (Ingebritsen et al. , 1983a) and the related
inhibitor, dopamine and cAMP-regulated phosphoprotein (DARPP)) and
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protein kinases (eg. the regulatory subunit of cAMP-dependent protein 
kinase (Blumenthal et al. , 1986)). It may thus be involved in a 
protein phosphatase cascade system whereby the activation of PP-2B by 
Ca2H" results in the inactivation of inhibitor-1 and hence the 
activation of PP-1.
The importance of the protein phosphatases has been further 
demonstrated by Haystead et al. (1989), who have shown that the 
potent tumour promoter, okadaic acid, acts by being an inhibitor of 
two protein phosphatases, 1 and 2A. It stimulated increased 
phosphorylation in intact adipocytes and in the latter mimicked the 
effects of glucagon on glycogenolysis and gluconeogenesis. However, 
although the importance of protein phosphatases is now apparent, they 
are, as yet, less well understood than protein kinases.
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C. Protein Kinases and Viral Infection.
The infection of eukaryotic cells with many viruses has been 
found to result in the phosphorylation of proteins of both viral
(Wilcox et al., 1980) and cellular origin (Kennedy et al. , 1981). In
principle, these phosphorylations might be catalysed either by 
protein kinases which are associated with the virions or by protein 
kinases induced or activated during infection.
Protein kinase activities have been found to be present within 
the virions of many enveloped viruses eg. vesicular stomatitis virus 
(VSV ; Clinton et al., 1982), RNA tumour viruses (Weiss & Faras,
1983), influenza virus (Karaata, 1977) and also some non-enveloped 
viruses eg. polio virus (Lackmann et al. , 1987). Such enzyme
activities have been detected by incubating pure virions in the 
presence of yC3:Z:P3ATP, and examining the radioactive labelling of 
virion proteins or exogenous substrates such as protamine, casein or
histones. Some of these virion protein kinases have been
characterised with respect to protein substrate specificity, 
requirements for divalent cations, and whether ATP and GTP may be 
used as the donor for the phosphoryl residue. From such studies it 
has become apparent that many of the protein kinases present within 
virions have very similar catalytic properties to known cellular 
protein kinases and thus probably are cellular enzymes which have 
become incorporated within the virion during its assembly. For 
example, a protein kinase associated with the virion of VSV has been
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shown conclusively to be the cellular protein, pp60*r',= (Clinton 
et al., 1982). The protein kinase can be immunoprecipitated from VSV 
virions with anti-serum which specifically recognises pp60“rc.
The protein kinase activities associated with the virions of 
a-herpes viruses were investigated by Lemaster & Roizman (1980) and 
Stevely et al. (1985). Lemaster & Roizman showed that virions of 
HSV-1 and HSV-2 contained endogenous protein kinase activity which 
was able to phosphorylate a number of virion proteins. Stevely 
et al. showed that the endogenous protein kinase activity of HSV-1 
and PRV virions could be attributed to multiple protein kinases. PRV 
was found to contain at least four different protein kinases, two of 
which could use casein and two which used protamine as a substrate. 
Further characterisation of the former protein kinases suggested that 
they were the cellular protein kinases, casein kinase I and II. The 
properties of one of the protamine protein kinases suggested that it 
might be protein kinase C, also of cellular origin. It is unclear 
whether this incorporation of cellular enzymes into virions is 
functionally significant or occurs adventitiously during the assembly 
of the virion.
Protein kinases of viral origin (ie. encoded by the viral 
genome) could also be present within virions. In order to prove that 
a protein kinase is of viral origin, it is necessary to identify the 
viral gene which encodes it. As has been discussed above, protein 
kinase genes can be tentatively identified from their sequences.
Since the genomes of most well-studied viruses have been sequenced in 
their entirety, it should be quite easy to determine whether there is 
a putative protein kinase\present within their genome. So far only
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the genomes of a-herpes viruses have been shown conclusively to 
encode a viral protein kinase ie. the US3 gene of HSV-1 and its 
homologues in HSV-2 and VZV (McGeoch & Davison, 1986).
Many acutely oncogenic retroviruses are also known to encode 
protein kinases (Sefton, 1985). Indeed, the genes encoding many of 
the cellular tyrosine protein kinases were initially identified as 
the cellular homologues of oncogenes carried by particular oncogenic 
retroviruses. Although these protein kinases are encoded in viral 
genomes, they are not true viral protein kinases in that they are 
acquired from the cellular genome by the retroviruses. Since there 
is a limit to the size of the viral genome, the cellular gene is 
usually acquired at the expence of part of the normal retroviral 
genome, thus giving rise to a defective virus which is unable to 
replicate or undergo productive infection alone (Gross, 1983). The 
recent cellular origin of such protein kinases is evident from the 
nucleotide sequences of the genes, which are almost identical to that 
of the cellular homologues (Takeya & Hanafusa, 1983).
The protein kinases of HSV-1 and PRV
The protein kinase activity which is the main concern of the 
work described here, was first observed in the cytoplasm of baby 
hamster kidney fibroblasts (BHK cells) infected with PRV (Mcgarvey, 
1981). It was found to appear 4h after infection and increased in 
amount up to lOh after infection (Katan et al. , 1985). This activity 
was purified 100-fold by Katan et al. and characterised. It was 
found to phosphorylate serine residues of basic proteins, showing a
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preference for protamine over mixed histones. It was specific for 
ATP as the phosphate donor and could not utilise GTP. The activity 
was refractory to molecules known to affect the activity of other 
protein kinases: cAMP, cGMP, Ca2-/calmodulin, Ca^/phospholipid, 
double-stranded RNA and heparin. A distinguishing feature of the 
enzyme was that it retained its activity in salt concentrations up to 
0. 8M KC1.
Purves et al. (1986b) detected an analogous protein kinase 
activity in BHK cells infected with HSV-1. The kinetics of the 
appearance of both protein kinases were similar to those of the viral 
DNA polymerase. For both protein kinases, the activity induced in 
infected cells was related to the multiplicity of infection, and 
viruses which had been subjected to ultra-violet radiation did not 
induce the protein kinase activity. Infection with a temperature- 
sensitive mutant of HSV-1 induced the protein kinase when grown at 
the permissive temperature but not at the restrictive temperature. 
This evidence, together with the observation of different 
chromatographic properties for the protein kinases induced by HSV-1 
and PRV, suggested - but did not prove - that these enzymes were 
encoded by the viral genomes.
The substrate specificities of the protein kinases induced by 
infection with HSV-1 (HSV-PK) and PRV (PRV-PfO were investigated 
using peptide substrates and compared to those of other protein 
kinases (Purves et al. , 1986a). Both protein kinases could 
phosphorylate seryl and threonyl residues and showed a preference for 
peptides with arginine residues on the N-terminal side of the 
seryl/threonyl residue, but were not able to phosphorylate similar
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peptides in which ornithine replaced the arginine. Peptides with 
arginyl residues only on the C-terminal side of the seryl residue 
were also inefficient substrates. This specificity contrasted to 
that of protein kinase C, which can phosphorylate peptides having 
arginyl residues on either side of the seryl residue and also 
peptides in which arginine is replaced with ornithine. The peptides 
phosphorylated by PRV-PK and HSV-PK could also be phosphorylated by 
cAMP-dependent protein kinase, but the reaction preferences were 
different for the latter. The fact that the substrate specificities 
of both enzymes appears to be very similar suggests that PRV-PK and 
HSV-PK are related proteins despite their different chromatographic 
properties.
Purves et al. (1987a) purified PRV-PK to homogeneity at a 
specific activity of approximately lOOOnmol phosphate mg-1, min-1. 
Analysis of the purified enzyme by gel electrophoresis under 
denaturing conditions revealed a single band corresponding to a 
molecular weight of 38kDa, and this band became labelled when the 
pure enzyme was incubated with yC32P]ATP in the absence of other 
substrates. The isoelectric point of the phosphorylated species was 
approximately 4. 9.
HSV-PK was purified 100-fold (Frame et al. , 1987b). The 
resulting material consisted of two proteins of 65kDa and 68kDa, of 
which only the latter could be labelled when this material was 
incubated with y£32P^ATP. This could either be due to 
autophosphorylation, as with PRV-PK, or to phosphorylation of the 
68kDa protein by another protein kinase (eg. the 65kDa protein) in 
the preparation.
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Two approaches were used to determine the genetic origin of the 
protein kinase induced by infection with HSV-1, both of which were 
possible because the sequence of part of the genome of HSV-1 was 
known. This allowed the US3 gene to be identified as a candidate for
encoding a viral protein kinase (McGeoch & Davison, 1986). The first
approach involved raising anti-sera against an oligopeptide 
consisting of the predicted 8 amino acids at the C-terminus of the 
US3 gene (Frame et al. , 1987). In immunoblots, this anti-serum was 
found to react with the 68kDa band of the highly purified protein 
kinase. Although this showed that the 68kDa band was the product of 
the US3 gene, it was still formally possible that the 65kDa band 
contained the HSV-PK activity. The second approach involved the use 
of a mutant virus which lacked the US3 gene (Purves et al. , 1987b). 
This mutant virus could infect BHK cells effectively, as assessed by 
the yield of virus, but did not induce HSV-PK. Although it was still 
possible that the US3 gene might have been only indirectly involved 
in the induction of the protein kinase activity, taken together, 
these two pieces of work strongly supported the conclusion that
HSV-PK is the product of the gene, US3.
During the course of the present work, a protein kinase gene, 
pk, equivalent to the US3 gene of HSV-1, was identified within the 
Bam HI-10 fragment of the PRV genome and sequenced (G. Zhang et al., 
1989 : fig 1.3). The gene was predicted to encode a protein of 334 
amino acids and thus appeared to be of approximately the correct size 
to encode the 38kDa protein kinase, PRV-PK.
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The aims of this work were four-fold: first, to determine if the 
putative protein kinase gene, pk, identified in the Bam HI-LO 
fragment of the genome of PRV encodes the protein kinase (PRV-PK) 
induced during infection of cells with PRV, and hence to determine if 
PRV-PK is of viral origin; second, to investigate the location of the 
product of the pk gene in both infected cells and within virions; 
third, to identify possible physiological substrates of both protein 
kinases, which might help shed light on the function of these enzymes 
in infection of cells with a-herpes viruses; and fourth, to determine 
if expression or over-expression of HSV-PK, in the absence of other 
viral proteins, could cause malignant transformation or other 
phenotypic changes to cells in culture.
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Figure 1. 1
Schematic diagram showing the arrangement of the genomes of HSV-1, 
PRV and EBV.
UL represents unique long region.
US represents unique short region.
Shaded areas represent large repeats, with the arrows indicating the 
orientation of the repeat.
Open boxes in EBV represent direct repeats of a 2kbp sequence. 
Vertical lines represent short terminal reiterations (direct 
repeats).
Numbers indicate the molecular mass of region in kDa.
(Roizman & Batterson, 1985).
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Figure 1. 2
Schematic diagram of Us and Rs regions from the genomes of PRV, HSV-1 
and VZV, showing homologous genes.
Arrows indicate the direction of transcription of the genes.
In HSV-1, the open reading frames of US10 and US11 overlap.
(Rea et al., 1985; Davison & McGeoch, 1986; Petrovskis et al., 1986a; 
Petrovskis et al., 1986b; Petrovskis & Post, 1987)
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Figure 1. 3
a) Schematic diagram showing the Baa HI cleavage sites in the PRV 
genome.
The cleavage sites are marked as arrows and the resulting fragments 
are numbered according to their size when subjected to 
electrophoresis on agarose gels. The inverted repeats of the genome 
are indicated by shaded boxes CPetrovskis et al., 1986).
b) Schematic diagram of Bam HI fragments 7 and 10 of the PRV genome.
Shaded boxes represent the positions of the genes which have been 
identified. (There is also a small Bam HI fragment of 0. 2kb between 
fragments 7 and 10. )
(Rea et al., 1985; Petrovskis et al., 1986a; Petrovskis ef al.,
1986b; Petrovskis & Post, 1987)
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SUBDOMAIN SHARED SEQUENCE MOTIF
I G - G  G - V
II A - K
VI ser/thr h r D l K - - N
tyr (src family) H R D L , R A A N
tyr (others) H R D L A A  R N
VII D F G
VTII ser/thr a p E
tyr p - (K/R) t f - a p E
IX D - W (S/A) - G
Figure 1. 4
Shared sequence motifs of the conserved subdomains within the 
catalytic domain of protein kinases. (Hanks et al., 1988)
The single-letter amino acid code is used. Upper case letters which 
are underlined represent residues which are completely conserved in 
all known protein kinases. Upper case letters which are not 
underlined represent highly conserved residues or residues which 
undergo conservative changes. Lower case letters represent 
moderately conserved residues or residues which are highly conserved 
but can undergo non-conservative changes.
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Table I
IMMEDIATE-EARLY PROTEINS OF HSV-1
references:
1) Everett, 1984
2) Perry et al., 1986 
3> Proton, 1979
4) Preston, 1981
5) Post & Roizman, 1981
6) Everett, 1986
7) Longnecker & Roizman, 1986
8) Mavromara-Nazos et al. , 1986
Table II 
GLYCOPROTEINS OF HSV-1
ref erences:
1) Pellett et al., 1985 
2> Little et al., 1981
3) Frink et al., 1983
4) Watson et al., 1982
5) Longnecker & Roizman, 1986
6) Neidhardt et al. , 1987
7) Longnecker & Roizman, 1987
8) Weber et al, , 1987
9) Gompels & Minson, 1986
10) Longnecker et al., 1987
Table III
PROTEINS OF HSV-1 ESSENTIAL AND SUFFICIENT FOR DNA REPLICATION
ref erences:
1) Wu et al., 1988
2) McGeoch et al. , 1988b
3) Quinn & McGeoch, 1985 
4> Parris et al., 1988
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Table I
IMNEDIATE-EARLY PROTEINS OF HSV-1
gene IE designation a designation function
RL<1) IE 110 ctO transactivation
RS( 1) IE 175 a4 transactivation
US1 IE 58 a22 ? dispensable
UL54 IE 63 all transactivation
US 12 IE 12 ail ? dispensable
reference
1,
3,
5
6 
7,
Table II 
GLYCOPROTEINS OF HSV-1
gene
UL27
UL44
US6
US8
US 4
UL22
US7
protein
g® 
gC
gD
gE 
gG
gH
gl
abundance
major
major
major
major
minor
minor
minor
function
essential
dispensable
essential
dispensable
dispensable
essential
dispensable
ref erence
1, 2
3
4
5, 6 
7, 8
9
10
Table III
PROTEINS OF HSV-1 ESSENTIAL AND SUFFICIENT FOR DNA REPLICATION
gene
UL5
UL8
UL9
UL29
UL30
UL42
UL52
protein
component of helicase-primase complex 
component of helicase-primase complex 
origin-binding protein 
major DNA-binding protein 
DNA polymerase 
? binds double-stranded DNA 
component of helicase-primase complex
reference
1, 2 
1, 2 
1, 2 
3 
3
1, 2 , 
1, 2
Table IV
OTHER ENZYMES ENCODED BY THE GENOME OF HSV-1
ref erences:
1> Kit & Dubbs, 1963
2) Wagner et al., 1981
3) Preston et al., 1984
4) McLauchlan, 1983
5) Preston & Fisher, 1984
6) Fisher & Preston, 1986
7) Worrad & Caradonna, 1988 
8> Draper et al., 1986
9) Purves et al., 1987b
10) Chee et al. , 1989
11) Smith & Smith, 1989
Table V
GENES ENCODING VIRION PROTEINS OF HSV-1
ref erences:
1) Costa et al. , 1984 
2> Davison & Scott, 1986b
3) Preston et al., 1983
4) Kwong et al., 1988
5) Campbell et al., 1984
6) Dalrymple et al. , 1985
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Table IV
OTHER ENZYMES ENCODED BY THE GENOME OF HSV-1
gene
UL23
UL39
UL50
UL2
UL12
US3
UL13
gene
UL19
UL26
UL41
UL48
enzyme f unction reference
thymidine kinase dispensable
and 40 ribonucleotide reductase dispensable
dUTPase dispensable
uracil-DNA glycosylase dispensable
exonuclease essential
protein kinase dispensable
? protein kinase ?
1,
3,
5,
7
8 
9 
10, 11
Table V
GENES ENCODING VIRION PROTEINS OF HSV-1
protein reference
VP5, major structural component of virions 1, 2
VP22a, surface component of virions 3
protein which shuts off host protein synthesis 4
Vmw65, major tegument protein which activates 5, 6
expression of immediate-early genes
Table VI
EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
HAVING NARROW SUBSTRATE SPECIFICITIES
ref erences:
I) Pickett-Gies & Walsh, 1986 
2> Stull et al., 1986
3) Nairn & Greengard, 1987
4) Nairn et al., 1985
5) Ryazanov, 1987
6> Blenis et al., 1987
7) London, et al., 1987
8) Reed & Yeaman, 1987
9) Randle et al., 1987
10) Frank & Buzney, 1975
II) Benovic et al., 1986
12) Hardie et al., 1989
13) Emki et al., 1980
14) Hemmings et al., 1981
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Table VI
EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
HAVING NARROW SUBSTRATE SPECIFICITIES
PROTEIN KINASE CPK)
phosphorylase b 
kinase
myosin light chain 
kinase
Ca^/CaM-dependent
PKI
Ca^/CaM-dependent 
PKI I
Ca2-VCaM-dependent
PKIII
S6 kinase
haem-regulated PK
ds RNA-dependent PK
pyruvate dehydrogenase 
kinase
branched chain <x keto 
acid dehydrogenase 
kinase
rhodopsin kinase
3 adrenergic receptor 
kinase;
AMP-PK
glycogen synthase 
kinase 3
SUBSTRATES
phosphorylase b
myosin light chain
synapsin I (site I), 
protein III
REGULATION
activated by Ca2+",
4. ATP, t ADP
activated by 
Ca2-/CaM
activated by 
Ca2-VCaM
glycogen synthase, activated by 
synapsin I (site II), Ca^/CaM 
tryptophan hydroxylase,
MAP-2
REF
1
EF-2 activated by 
Ca2VCaM
ribosomal protein S6 ? activated by
mitogens
eIF-2cx
eIF-2a
pyruvate
dehydrogenase
inhibited by haem 7
activated by ds RNA 7
activated by Tacetyl 8 
CoA and NADH, ■i'ATP, 
high [pyruvate]
branched chain a keto inhibited by ADP, 
acid dehydrogenase acetoacetyl CoA,
branched chain 
keto acids
rhodopsin
3 adrenergic receptor 
(occupied by agonist)
10
11
hydroxymethylglutaryl AMP, phosphorylation 12 
CoA reductase. by kinase kinase
acetyl CoA carboxylase;
i?l ycofirsn synt h9S6j 
PP-inhibitor 2 
cAMP-dependent PK RIj:
13 
& 14
Table VII
EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
HAVING BROAD SUBSTRATE SPECIFICITIES
ref erencesj
1) Beebe & Corbin, 1986
2) Nishizuka, 1986
3> Ahmad et al., 1984
4) Pendergast & Traugh, 1985
The one letter amino acid code is used, with X indicating any 
amino acid.
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Table VII
EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
HAVING BROAD SUBSTRATE SPECIFICITES
PROTEIN KINASE
cAMP-dependent 
protein kinase
cGMP-dependent 
protein kinase
protein 
kinase C
casein 
kinase I
casein 
kinase II
REGULATION SUBSTRATE
SPECIFICITY
EXAMPLES OF 
SUBSTRATES
REF
cAMP RRXS phosphorylase 
kinase, acetyl 
CoA carboxylase, 
myosin light 
chain kinase
cGMP CnM) 
cAMP <|xM>
Ca2*- +
diacylglycerol
basic-PS-basic
basic residues 
on N- or C-side 
of S/T
EGF receptor, 
acetyl CoA 
carboxylase
inhibited by 
heparin,
2, 3 diphospho- 
glycerate, 
activated by 
polyamines
acidic amino 
acids on C-side 
of S/T
glycogen synthase, 
amino-acyl tRNA 
synthase 3,4
glycogen synthase, 
acetyl CoA 
carboxylase, DNA 
topoisomerase II
1
Table Villa
PROTEIN KINASES KNOWN TO UNDERGO AUTOPHOSPHORYLATION
SERINE/THREONINE PROTEIN KINASES
ref erences:
1) Rangel-Aldao & Rosen, 1976
2) Todhunter & Purich, 1977
3) Hoffmann & Flockerzi, 1983
4) Aitken et al., 1984
5) Hallenbeck & Walsh, 1983
6) Lai et al., 1987
7) Kikkawa et al., 1982
8> Gross & Mendelewski, 1978 
9> Berry & Samuel, 1985
10) Ahmad et al., 1984
11) Dahmus, 1981
12) Lee et al., 1982
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Table Villa
PROTEIN KINASES KNOWN TO UNDERGO AUTOPHOSPHORYLATION
PROTEIN KINASE 
(pk>
SERINE/THREONINE 
PROTEIN KINASES
cAMP-dependent pk 
cGMP-dependent pk
phosphorylase b 
kinase
Ca2H"/CaM-dependent 
pk II
protein kinase C
haem-regulated pk 
ds RNA-dependent pk 
casein kinase I 
casein kinase II 
rhodopsin kinase
SITE OF AUTO- EFFECT OF AUTO- REF
PHOSPHORYLATION PHOSPHORYLATION
Rri subunit, ser 95 reassociation with 1
C-subunit &2
thr 58 taffinity for cAMP, 3
no effect on affinity
for cGMP
activation 5
a and (J subunits activity independent of
Ca*VCaM 6
^affinity for Ca2"* and 
diacylglycerol 7
3-5 sites activation 8
activation 9
no effect 10
no effect 11
? 12
Table Vlllb
PROTEIN KINASES KNOWN TO UNDERGO AUTOPHOSPHORYLATION
TYROSINE PROTEIN KINASES
ref erences:
1> Smart et al., 1981
2) Cooper et al., 1986
3) Tornqvist & Avruch, 1988
4) Tornqvist et al. , 1988
5) Cooper et al., 1981
6) Stern et al., 1986
7) Meckling-Hasen et al., 1987 
8> Weinmaster et al., 1983
9) Reynolds et al., 1982
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Table VUIb
PROTEIN KINASES KNOWN TO UNDERGO AUTOPHOSPHORYLATION
PROTEIN KINASE 
(pk)
TYROSINE PROTEIN 
KINASES
pp60
pp60c:~*,,''::
insulin receptor
EGF receptor 
neu protein 
v-fgr protein
v-fps protein
v-abl protein
SITE OF AUTO- EFFECT OF AUTO- REF
PHOSPHORYLATION PHOSPHORYLATION
major site tyr 416
major site tyr 527
activation of protein 1 
kinase and trans­
forming activity
activation of protein 2 
kinase and trans­
forming activity
6 sites, most 
important: tyr 1146, 
1150 and 1151
activation of pk
tyr 553 (equivalent 
to tyr 416 of v-src)
tyr 1073 (equivalent 
to tyr 416 of v-src)
tyr 514 (equivalent 
to tyr 416 of v-src)
activation of pk 
activation of pk
3,4
5
6 
7
Table IX
PROTEIN KINASES INVOLVED IN THE REGULATION OF CELL GROWTH
ref erences:
1) Hanks et al. , 1988
2) Hunter & Cooper, 1986
3) Van Beveren et al. , 1981
4) Koenen et al. , 1988
5) Beck et al. , 1987
6> Dunphy & Newport, 1988
7) Russel & Nurse, 1987a
8) Russel & Nurse, 1987b
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Table IX
PROTEIN KINASES INVOLVED IN THE REGULATION OF CELL GROWTH
TYROSINE PROTEIN KINASES FUNCTION
src family: regulation of cell
protein products of proliferation
src, yes, fgr, lyn, 
lck, fyn, hck
receptors for hormones and growth factors: response to hormones
EGF receptor, neu protein, and growth factors
insulin receptor, IGF-1 receptor,
CSF-1 receptor, kit protein,
PDGF receptor, ros protein, 
met protein, ret protein
SERINE PROTEIN KINASES
mos/mll/raf protein
CDC28/cdc2/MPF/histone HI kinase
weel'h protien
regulation of cell 
proliferation
required for 
transitions in the 
cell cycle: 
interphase to Gl,
G2 to mitosis
negative regulation 
of cdc2 protein
REF
1,2
1,2
3,4
6 5
6
7
n i m l protein negative regulation 8 
of weel"* protein
Table X
FUNCTIONS OF EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
ref erences:
1) Pickett-Gies & Walsh, 1986
2) Kamm & Stull, 1985
3) Stull et al., 1986
4) Nairn & Greengard, 1987
5) Nairn et al., 1985
6) Palfrey et al., 1987
7) Blenis et al., 1987
8) London et al. , 1987
9) Reed & Yeaman, 1987
10) Randle et al., 1987
11) Strasser et al., 1986
12) Sitaramayya & Liebman, 1983
13) Hardie et al., 1989
14) Cohen, 1986
15) Cohen, 1985
16) Beebe, 1986
17) Nishizuka, 1986
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Table X
FUNCTIONS OF EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
PROTEIN KINASE FUNCTION REF
phosphorylase b 
kinase
myosin light chain 
protein kinase
activates glycogen phosphorylase, which 
catalyses glycogen breakdown
smooth muscle and non muscle:
phosphorylation of myosin light chain 
is essential for the activation of 
myosin ATPase by act in 
skeletal and cardiac muscle:
phosphorylation of myosin light chain; 
not essential, but modulates contraction
Ca^/CaM-dependent 
protein kinase I
Ca'^/CaM-dependent 
protein kinase II
phosphorylation of synapsin I, which is 
involved in neurotransmitter release
phosphorylation of synapsin I and MAP-2, 
which are involved in neurotransmitter 
release
4,5
Ca2"VCaM-dependent phosphorylation of EF-2, causes inhibition 6
of protein kinase III protein synthesis
S6 kinase involved in cell growth 7
haem-regulated phosphorylation of eIF-2a, causes inhibition 8
protein kinase of translation
ds RNA-dependent phosphorylation of eIF-2a, causes inhibition 8
protein kinase of translation
pyruvate inhibition of pyruvate dehydrogenase 9
dehydrogenase kinase
branched chain a keto inhibition of branched chain a keto acid 10
acid dehydrogenase dehydrogenase, causing inhibition of
kinase oxidation of leucine, isoleucine and valine
Table X (continued)
FUNCTIONS OF EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
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Table X (continued)
FUNCTIONS OF EUKARYOTIC SERINE/THREONINE PROTEIN KINASES
PROTEIN KINASE
3 adrenergic 
receptor kinase
rhodopsin kinase
AMP-dependent 
protein kinase
glycogen synthase 
kinase 3
cAMP-dependent 
protein kinase
protein kinase C
FUNCTION
phosphorylation of receptor, desensitises 
receptor towards adrenalin
phosphorylation of rhodopsin prevents 
association with G^GTP which prevents 
activation of cGMP phosphodiesterase
inactivation of acetyl CoA carboxylase 
and HMG CoA reductase, causes inhibition 
of fatty acid and cholestrol synthesis
inactivation of glycogen synthase causing 
inhibition of glycogen synthesis
regulation of:
glycogen synthesis/glycogenolysis 
gluconeogenesis/glycolysis 
fatty acid synthesis/lipolysis 
cholestrol ester hydrolysis 
catecholamine synthesis 
aromatic amino acid degradation
release of hormones and neurotransmitters, 
activation of T and B lymphocytes, 
muscle contraction and relaxation
Table XI
CHARACTERISTICS OF PROTEIN PHOSPHATASES
ref erence:
Ingebritsen & Cohen, 1983
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Table XI
CHARACTERISTICS OF PROTEIN PHOSPHATASES
protein
phosphatase
PP-1
PP-2A
PP-2B
abundance substrate
specificity
high broad
high broad
low narrow eg.
inhibitor-1, 
cAMP-dependent pi 
Rji subunit
regulators
inhibitor-1 and -2 
glycogen synthase 
kinase 3
unknown 
Ca2  ^and CaM
PP-2C high broad
Chapter 2 
MATERIALS AND METHODS
A. Materials
1. Radlochemlcals
The following radlochemlcals were obtained from Amershaat 
International pic, England.
y[sap]ATP as TEA salt in stabilised aqueous solution at lOmCl/ml 
and 5000Ci/mmol, C32P]orthophosphate in dilute HC1 pH 2.3 carrier 
free lOmCi/ml.
2. Fine chemicals
Fine chemicals were AnalaR Grade supplied by BDH Chemicals Ltd or 
Formachent (Research International) Ltd, with the exception of those 
listed below.
The following were obtained from Amersham International Ltd, England.
Rainbow protein molecular weight markers (pre-stained proteins 
with molecular weights of 200kDa, 96kDa, 69kDa, 46kDa, 30kDa,
21. 5kDa, 14. 3kDa>.
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The following, a product of Toyo Soda Manufacturing Co. (Japan) was 
obtained through Anachem, Luton.
TSK phenyl-5PW column.
The following were obtained from Bethesda Research Laboratories or 
New England Biolabs.
restriction endonucleases, low melting point agarose (ultra
pure)
The following was obtained from Biorad Laboratories 
Biogel P60
The following was obtained from Calbiocheit-Behring.
Aquacide (type II)
The following were obtained from Dlfco Laboratories, West Molesey, 
Surrey, England.
bacto agar (0140-01), bacto tryptone (0123-01), nutrient broth 
(0003-02), tryptose phosphate, yeast extract (1880-17)
The following were obtained from Eastman Kodak Co, USA.
N, N, N', N'-tetramethyl-ethylene diamine (TEMED), Bromophenol Blue
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The following were obtained from Gibco Biocult, Scotland, 
heat-inactivated horse serum, new-born calf serum,
Dulbecco modified Eagle's minimum essential medium (D-MEM x 10), 
Glasgow modification of Eagle's minimum essential medium 
CG-MEM x 10), 7.5% NaHC03 pH7. 4, L-glutamine x 100 (200mM), 
penicillin/streptomycin (lOOOOIU/ml penicillin, lOOOOUG/ml 
streptomycin), trypsin (0.25%), MEM amino acids without 
L-glutamine x50, MEM vitamins x 100
The following was obtained from Fuji Photo Film Co., Ltd,
Fuji X-ray film
The following was obtained from Pharmacia, Sweden, 
aminohexyl (AH)-Sepharose 4B
The following was obtained from Schleicher & Schuell, Anderman & Co
Ltd, Surrey, England.
nitrocellulose membrane filters
The following was obtained from Scottish Antibody Production Unit,
Law Hospital, Carluke, Lanarkshire.
horse radish peroxidase-coupled donkey anti-rabbit 
immunoglobulin G
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The following were obtained from Sigma Chemical Co
agarose type II, alkaline phosphatase-conjugated goat 
anti-rabbit IgG, ampicillin, Brij 58, 5-bromo-4-chloro-
3-indolyl phosphate (p-toluidine salt), chloramphenicol,
4-chloro-l-napthol, Coomassie Blue G 250 and R 250,
DNase I (bovine pancreas), diethylpyrocarbonate, 
hydrogen peroxide, lysozyme, nitroblue tetrazolium, 
N-laurylsarcosine, NP-40, phenylmethylsulphonyl 
fluoride, protamine-agarose, protamine sulphate (salmine), 
RNAase A (bovine pancreas), Sephacryl S300, L-threonine, 
Tween 20
The following were obtained from Whatman Biochemicals Ltd
DEAE-cellulose (DE-52), 3MM filter paper, 3MM filter discs
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3. Cell lines
BHK 21/C13 i baby hamster kidney fibroblasts (MacPherson & 
Stoker, 1962)
208F : rat fibroblasts from D. Spandidos, Beatson Institute for 
Cancer Research, Garscube Estate, Bearsden, Glasgow. (Quade, 1979)
4. Viruses
PRV was originally obtained from Kaplan & Vatter (1959) via 
W. S. Stevely.
HSV-1 Glasgow strain 17 was from J. MacNab, MRC Virology Unit, 
Institute of Virology, University of Glasgow.
HSV-1 R7041, a mutant in which the US3 gene is deleted 
(Purves e t al., 1987b), was a gift from B. Roizman.
5. Bacteria
The strain of E. c o l i used was JM109 which has the genotype:
recAl, b la c  pro. end Al, g y r A96, th i-1 ,  had R17, sup E44, 
r e l Al/F*, t r a  D36, pro AB-, la c Iq, la c  z b M15. 
(Yanish-Perron et a l . , 1985)
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6. Plasmids
The plasmids used are described below.
pIC 20H is a vector with multiple cloning sites, flanked by two 
Hind III sites, all of which occur within la c  z. This allows colour 
selection of recombinants, (Marsh e t a l . , 1984).
pUEXl-3 are a family of vectors which allow expression of a 
fragment of DNA as a p-galactosidase fusion-protein in E. c o li  
(Bressan & Stanley 1987).
Homer 5 is a vector allowing the expression of eukaryotic genes 
from their own promoter but with the expression enhanced by the SV 40 
enhancer sequence. This vector also allows selection for 
transformants by geneticin resistance. (Spandidos & Anderson, 1987) 
pRB 425 consists of the Hind III - Sst I fragment 
(bases 862-5337) of HSV-1 F strain cloned into pUC 18. This was a 
gift from B. Roizman (Longnecker & Roizman, 1987).
pPRVB 10 consists of the Bam HI fragment 10 of PRV cloned into 
pUC 18 and was a gift from G. Zhang (Petrovskis e t a l . , 1986).
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B. Methods
1. E. c o l i culture
L-broth: lOg bactotryptone, 5g yeast extract, 5g NaCl in 11 water 
L-Agar : 15g agar In 11 L-broth 
ampicillin stock: 5mg/ml stored at -20°C
Hammersmith stabs: 0. 9g nutrient broth, 0. 75g agar, 0. 5g NaCl in
100ml water, plus 1ml of lOmg/ral thymidine 
M9 salts: 6g Na2HP0A, 3g KH2P0A, 0. 5g NaCl, lg NHAC1 in 500ml 
water
Minimal Agar: 500ml M9 salts, 500ml 3% agar, 1ml 1M MgS0A, 
lml 0. 1M CaCl2, 1ml 1M thiamine-HCl,
5ml 40% glucose 
IPTG stock: 20mg/ml in water, stored at 4°C 
X-gal: 20mg/ml in dimethylformamide, stored at -20°C
E. c o l i JM109 was maintained on minimal agar plates.
Transformed E. c o l i colonies were grown on ampicillin plates
ie. 30pg/ml ampicillin in L-agar, or in liquid culture with 20pg/ml
ampicillin in L-broth.
Transformed E. c o l i colonies were stored as Hammersmith stabs at room 
temperature.
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1. 1 Preparation of competent cells for transformation
An overnight culture was inoculated from a single colony of JM109 • 
from a minimal agar plate. 40ml of L-broth were inoculated with 2ml 
of the overnight culture and incubated at 37°C for 3h. The cells 
were then harvested by centrifugation at 2000rpm for lOmin and 
resuspended in 20ml of pre-chilled 50mM CaCla. After 20min, the cells 
were centrifuged as before and then resuspended in 4ml 50mM CaCl2. 
These were suitable for use for up to 7 days after they had been 
prepared and were stored at 4°C.
1.2 Transformation of E. coli with plasmid DNA
0. 1-lng DNA was added to lOOpg competent cells and incubated on 
ice for 30min. The mixture was then incubated for 2min at 37°C, 
plated onto an ampicillin plate, and incubated at 37°C overnight.
For colour selection of recombinants in pIC 20H, the plates were 
spread with 30pl X-gal and 30pl IPTG before plating with the 
transformation mixture. Colonies containing recombinants were white, 
while those containing pIC 20H were blue.
2. Preparation of Plasmid DNA
2. 1 Small scale plasmid "mini-prep"
Single colonies from a transformation were streaked onto 
ampicillin plates so as to cover half a plate. (A master plate was 
also prepared. ) This was incubated at 37°C overnight.
The bacteria were scraped from the plate with a loop and 
resuspended in 1ml of a solution containing Q% sucrose, 50mM Tris-HCl
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pHd, 50mM EDTA, 5/* Triton X—100. 10|il of lOmg/ml Hz0 lysozyme were
added and mixed before incubating at 95-100°C for 7min. The tubes 
were then centrifuged for 15min and 0.6ml of the supernatant was 
transferred to another tube. 2pl lmg/ml H20 boiled RNAase A was 
added and incubated for 15min at 37°C. lpl diethylpyrocarbonate was 
then added and the tube was incubated for a further lOmin at 65°C. 
After this, 0. 24ml 5M ammonium acetate and 0. 54ml isopropanol was 
added. The tubes were mixed and left in dry ice for 5min, before 
centrifuging for lOmin to precipitate the DNA. The precipitated DNA 
was then washed with 0.3M ammonium acetate, 70% isopropanol, dried by 
lyophilisation and dissolved in 30pl TE buffer (Methods 3).
2. 2 Large scale plasmid "mini-prep"
Single colonies from a transformation were inoculated into 10ml 
of L-broth + ampicillin (Methods 1) and incubated overnight at 37°C. 
lml of this culture was then used to inoculate 50ml L-broth which was 
incubated overnight at 37°C.
The cells were harvested by centrifugation for lOmin at 2000rpm 
and resuspended in 5ml 25% sucrose, 50mM Tris-HCl pH7. 5. lml 
lysosyme (40mg/ml H20> was added and incubated for lOmin on ice.
2ml 0. 5M EDTA pH8 was added and incubated for a further 20min.
0.6ml 10% NP-40 was added and the tubes inverted to mix well. The 
cell debris was sedimented by centrifuging for 25min at 30000rpm in a 
Ti50 rotor. The supernatant was then extracted twice with equal 
volumes of phenol: chloroform: isoamylalcohol (25:24:1) and 
lOOpl lOmg/ml Ha0 boiled RNAase A added. After incubating for 30min 
at 37°C, a further phenol: chloroform: iso&tm^ ltolijjjl extraction was
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performed and the DNA precipitated by adding 0. 1 volumes 3M sodium 
acetate and 0.5 volumes isopropanol, and leaving at room temperature 
for lh. The DNA was then sedimented by centrifuging for 25min at 
lOOOOrpm. After washing the DNA with 100% ethanol it was dried in a 
lyophiliser and resuspended in approximately 500pl TE buffer (Methods 
3).
2. 3 Large scale plasmid preparation
25ml of L-broth + ampicillin (Methods 1) was inoculated with a 
single colony containing the plasmid, usually obtained from a master 
plate (Methods 2.1), and incubated overnight.
Two flasks of 800ml L-broth were inoculated with 5ml of the 
overnight culture and grown till they gave an 0D2eo reading of 0.8. 
Chloramphenicol (25mg/ml ethanol) was added to give a final 
concentration of 165pg/ml and incubation was continued overnight.
The cells were harvested by centrifugation at 5000rpm for lOmin, 
resuspended in 9. 5ml 50mM glucose, lOmM EDTA, 25mM Tris-HCl pH8, and
0.5ml 40mg/ml H20 lysozyme added. After incubating on ice for 30min, 
20ml of a solution containing 0. 2M NaOH, 1% SDS were added and 
incubated for 5min on ice. Then 15ml 3M sodium acetate pH4. 8 were 
added and left on ice for lh. The cell debris was removed by 
centrifugation for 30min at 30000rpm in a Ti60 rotor. Isopropanol 
(0. 6 volume) was added to the supernatant which was left for lOmin at 
room temperature before centrifuging for 15min at 8000rpm. The DNA 
precipitate was dissolved in 30ml TE buffer and 28. 9g CsCl + 1.8ml 
lOmg/ml H20 ethidium bromide added. The solution was clarified by 
centrifugation for 30min at 1500rpm, and transferred to a VTi50 tube,
-53-
which was heat-sealed, and centrifuged overnight at 50000rpm in a 
VT150 rotor at 20°C.
The band of DNA was recovered by piercing the tube with a 
syringe needle (21G), and transferred to a VT165 tube, which was 
heat-sealed and centrifuged overnight at 65000rpm in a VTi65 rotor at 
20°C.
The DNA was recovered in a similar manner and the ethidium 
bromide removed by mixing the solution containing the DNA with an 
equal volume of isoamylalcohol, separating the aqueous and organic 
layers by centrifuging for 2min in a microfuge and removing the 
organic layer. This was repeated 4 or 5 times. The DNA was diluted 
two-fold with TE buffer and precipitated with 100% ethanol. After 
dissolving in TE buffer, the yield was estimated by measuring the 
AZ0O' 50pg/ml DNA gives an A2QO reading of 1. 0.
3. Manipulation of DNA
Solutions
TE buffer: lOmM Tris-HCl pH8, ImM EDTA
Restriction enzyme buffers:
Low salt : lOmM Tris-HCl pH7. 4, lOmM MgSO*, ImM DTT
Medium salt : lOmM Tris-HCl pH7. 4, lOmM MgSO*, ImM DTT,
50mM NaCl
High salt : lOmM Tris-HCl pH7. 4, lOmM MgSO*, ImM DTT,
lOOmM NaCl
Ligase buffer: 40mM Tris-HCl pH7. 6, lOmM MgCl2, ImM DTT
Alkaline phosphatase buffer: 50mM Tris-HCl pH8, lOmM MgCl2
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3. 1 Restriction endonuclease digestions
Digestions were carried out in a volume of 20-200pl (depending 
on the amount of DNA) using the appropriate restriction endonuclease 
buffer and an excess of the desired enzyme (ie. more than 1 unit/pg 
DNA, but not exceeding 0. 1 of the total reaction volume) for 2hr at 
the temperature recommended by the manufacturers.
3.2 Deproteinlsation with phenol
Protein was removed from restriction digestions by adding an 
equal volume of phenol saturated with TE buffer, mixing and 
centrifuging in order to separate the organic and aqueous layers.
The aqueous layer was collected and the process repeated. Residual 
phenol was removed by a similar extraction proceedure using ether in 
place of phenol.
3. 3 Ethanol precipitation of DNA
DNA was precipitated by adding 2 volumes ethanol and 0. 1 volumes 
3M sodium acetate. This was either left at -20°C overnight, or left 
in dry ice for 30min. The precipitate was recovered by 
centrifugation, and then dried in a lyophiliser before redissolving 
in TE buffer.
3. 4 Treatment of vector DNA with alkaline phosphatase
After digestion of vector DNA with restriction endonuclease 
(Methods 3. 1), deproteinlsation with phenol (Methods 3.2), and 
ethanol precipitation (Methods 3.3), the DNA was redissolved in 20pl 
phosphatase buffer (Methods 3). 15U alkaline phosphatase were added
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and the mixture was incubated for 30min at 37°C. The DNA was again 
deproteinated with phenol (Methods 3.2), precipitated with ethanol 
(Methods 3. 3) and redissolved in TE buffer.
3. 5 Ligation
Ligations were performed in a volume of 30pl using about Ijig 
each of vector and insert DNAs. These were incubated overnight at 
15°C with 3fil ligase buffer xlO, 3pl 5mM ATP and 1 unit T4 ligase. 
15pl were used in a transformation.
4. Elect rophoresls
4. 1 Electrophoresis of DNA in Agarose gels
TBE buffer : lOg Tris, 5. 5g boric acid, 0. 93g EDTA in 11 water 
to give a final pH of 8.3 
1% agarose gel: 0.6g agarose type II, 60ml TBE buffer,
3pl lOmg/ml ethidium bromide 
1% low melting point agarose gel: 1. 2g low melting point agarose, 
120ml TBE buffer, 6pl lOmg/ml ethidium bromide 
Sample loading buffer: 0. 5ml glycerol, 0.5ml TBE buffer,
5pl lOmg/ml bromophenol blue
a) Standard 1% agarose gels
DNA samples were mixed with 0. 1 volume sample buffer and loaded onto 
an agarose gel. Electrophoresis was carried out in TBE buffer with
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50pl lOmg/ml H20 ethidium bromide per litre, at 70V. The DNA was
visualised by illumination on an ultra-violet transilluminator. 
Photographs were taken using a Polaroid camera using a Polaroid film 
type 665.
b) Low melting point agarose gels
DNA samples were prepared and loaded onto the gel as for the
standard agarose gel, and electrophoresis was carried out in TBE
buffer containing 0.5mg/l ethidium bromide, at 30V. The DNA was
visualised by illumination on an ultra-violet transilluminator.
c) Elution of DNA from low melting point agarose gels
The desired band was cut from the gel and placed in a tube along 
with 200pl TE buffer and incubated at 65°C for lOmin, before 
extracting with phenol saturated with TE buffer which had been warmed 
to 37°C. The phenol was removed from the resulting aqueous layer by 
extraction with ether and the DNA precipitated with ethanol 
(Methods 3.3).
4.2 Electrophoresis of Proteins on Polyacrylamide gels
Electrophoresis buffer : 14. 4g glycine, 6g Tris, lg SDS in 11
water, giving a final pH of 8.3 
Sample loading buffer : 500pl 0. 5M Tris-HCl pH 6. 7,
250pl 2-mercaptoethanol,
250pl 20% SDS, 2ml glycerol,
50jil 0. 1% bromo-phenol blue 
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Polyacrylamide gel:
stacking 10% separating 12.5% separating 
gel gel gel
30% acrylamide in H20 2. 5ml
water 8. 7ml
20% SDS 0. 075ml
TEMED 0.005ml
10% ammonium 0. 5ml
persulphate
1. 5M Tris-HCl pH8. 8 
0. 5M Tris-HCl pH6. 7 3. 8ml
13. 3ml 
16. 5ml 
0. 2ml 
0.018ml 
0. 5ml
10. 0ml
16. 6ml 
13. 4ml 
0. 2ml 
0. 018ml 
0. 5ml
10. 0ml
Unless otherwise stated, 10% polyacrylamide gels were used.
4. 2a Cooma88ie Blue staining
Coomaasie Blue protein staining solution:
0. 25% w/v Coomassle Brilliant Blue R 250, 45% methanol, 
10% acetic acid, 45% water 
Destaining solution:
45% methanol, 10% acetic acid, 45% water
Protein samples were added to an equal volume of sample loading 
buffer and boiled for 3min before loading onto the gel. 
Electrophoresis was performed for 3-4h at 50mA and 300V in 
electrophoresis buffer. The gel was then soaked in staining solution
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for lh at room temperature and then in several changes of destaining 
solution.
4. 2b Sliver staining 
solutions:
fixative : 30% methanol, 10% acetic acid, 60% water
reducer : 30ral ethanol, 65ml water, 2. 5ml 4M sodium
acetate. The pH was adjusted to 6.0 and
lOOmg sodium thiosulphate added, 
silver reagent : 0. 1% w/v silver nitrate in water
plus 25pl/100ml 37% w/v formaldehyde 
developer : 2. 5% w/v sodium carbonate in H20 plus 
50pl/100ml 37% w/v formaldehyde 
stop solution : 1% acetic acid in water
The gel was soaked in fixative for 30min and then reducer for 
30min. After washing with water several times, the gel was soaked in
silver reagent for 30min and washed with water before adding the
developer. Once the bands had developed, the reaction was stopped by 
adding the stop solution.
4.2c Acetone precipitation of proteins
10 volumes of acetone were added to the protein solution and 
left at 4°C overnight. The precipitate was sedimented by 
centrifugation at lOOOOrpm for 15min. Protein samples containing a 
high concentration of salt were dialysed against lOmM Tris-HCl pH7. 0 
before acetone precipitation.
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5. Cell Culture
Culture media
D—MEM growth medium:
450ml water, 50ml D-MEM xlO, 25ml 7. 5% NaHCOa pH7. 4,
5ml L-glutamine xlOO, 5ml penicillin/streptomycin,
50ml new-born calf serum 
G-MEM growth medium:
400ml water, 50ml G-MEM xlO, 12ml 7. 5% NaHC03 pH7. 4,
8ml L-glutamine xlOO, 4ml penicillin/streptomycin,
50ml new-born calf serum, 40ml tryptose phosphate broth
cell freezing media : 1)8% DMSO, 20% new-born calf serum,
72% D-MEM growth medium 
2) 10% sterile glycerol, 25% new-born calf 
serum, 65% G-MEM growth medium
Cell lines 208F, Ka-1, Ka-2, Kb-1 and Kb-2 were grown in D-MEM growth 
medium and stored in DMSO freezing medium.
BHK cells were grown in G-MEM growth medium and stored in glycerol 
freezing medium.
5. 1 Storage and recovery of cells
Cells were stored by freezing in liquid nitrogen. 5xl06 cells 
were trypsinised (by adding sufficient trypsin to cover the cells and
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incubating for i-5min at 37°C, and harvested by centrifuging for 5min 
at lOOOrpm. The supernatant was poured off and the cells resuspended 
in lml freezing medium, and transferred to a biofreeze vial. These 
were then frozen by wrapping in cotton wool and placing in a 
polystyrene box at -70°C overnight. They were then transferred to 
liquid nitrogen.
Cells were recovered from liquid nitrogen by thawing rapidly in a 
water bath at 37°C. The cells were then sedimented by centrifuging 
for 5min at lOOOrpm, resuspended in medium and added to a 25cma 
plastic flask containing 5ml medium, and 5% carbon dioxide.
5. 2 Growth of cells in culture
Cells were grown in plastic flasks or glass roller bottles 
(80oz>. 208F cells and the cell lines derived from these cells
<Ka-l, Ka-2, Kb-1, Kb-2> were grown in D-MEM growth medium. BHK 
cells were grown in G-MEM growth medium. For all cells, carbon 
dioxide was added to the flasks or roller bottles to give a final 
concentration of 5%. The table below shows the number of cells used 
to seed flasks and roller bottles to achieve confluence in 2-3 days.
size of flask inoculum of cells
25cm® 1x10*
75cm® 2x10®
150cm® 3-4x10®
80oz roller bottle 20-30x10*
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When confluent, the cells were trypsinlsed by adding sufficient 
trypsin to cover the cells and incubating for l-5min at 37°C. 5-25ml
growth medium were then added and the cells counted using a 
haemocytometer before using them to seed further flasks.
5. 3 Measurement of the growth of 208F cells and derived cell lines.
The growth of cells was measured over 10 days using either a 
Coulter counter or a haemocytometer to count the number of cells. 
Twenty two 60ram Petri dishes were seeded with 6x10* cells in 3ml 
D-MEM growth medium. These dishes were incubated at 37°C in an 
atmosphere of 5% carbon dioxide for the course of the experiment. On 
alternate days, half the medium was removed and replaced with fresh 
D-MEM growth medium. Each day, all the cells from one dish were 
harvested for counting. All the medium was removed and lml of 
trypsin added. The dish was incubated for approximately 5min at 37°C 
until the cells were released from the plastic. For counting with 
the Coulter counter, lml D-MEM growth medium was added and the cells 
transferred to a tube for counting. The dish was washed with lml PBS 
(Methods 8.2) and the washings together with a further 3ml PBS were 
added to the tube to give a final volume of 6ml. The cells were then 
counted three times with the Coulter counter and an average taken. 
Readings for the same sample varied by 0. 3% - 0. 57*. For counting 
with a haemocytometer, the volume was not increased above lml. A 
drop of the cell suspension was placed on the haemocytometer and 
counted.
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6. Infection of BHK cells with PRV
6. 1 Infection for preparation of virus stocks
Eight roller bottles (80oz) of BHK cells which were approximately 
80V confluent were infected with 0.02pfu/cell (50pl virus 
stock/roller bottle) in 100ml G-MEM growth medium but with only 1% 
new-born calf serum (Methods 5), and incubated for a further 24h by 
which time the cells were becoming detot'ched from the glass. The 
roller bottles were shaken to deta^ch all the cells and the medium 
poured off. This was stored in 500ml plastic bottles at -70°C and 
used as virus stocks for subsequent infections.
6.2 Infection for preparation of purified virions
Twenty roller bottles of confluent BHK cells were infected with 
5pfu/cell (5ml virus stock/roller bottle) in 20ml G-MEM growth medium 
with 1% new-born calf serum (Methods 5). After lh, this medium was 
poured off, and a further 20ml medium was added. The infection was 
continued for 18-24h, before harvesting (Methods 7. 1).
6.3 Infection for preparation of purified PRV-PK
30-40 roller bottles of confluent BHK cells were infected with 
20pfu/cell (20ml virus stock/roller bottle). After lh, this medium 
was poured off and replaced with 20ml fresh G-MEM growth medium with 
1% new-born calf serum (Methods 5). The infection was continued for 
8h, before harvesting (Methods 8.2a).
7. Preparation and extraction of PRV vlriona
7. 1 Preparation of Pseudorabies Virions (Stevely, 1975)
phosphate buffer : ImM Na2HPOA/KH2POA pH 7. 4
15% w/w sucrose in phosphate buffer
30% w/w sucrose in phosphate buffer
40% w/w sucrose In phosphate buffer
8M urea
Tris buffer: lOmM Tris-HCl pH 7.2, 0. 15M NaCl 
20% SDS in H20 
lmg/ml DNase I in H^O 
10% BriJ 58 in H20
18-24h after infection of BHK cells with PRV (Methods 6.2), the 
cells were scraped with a plastic scraper into the medium and 
harvested by subjection to centrifugation at 2000rpm for lOmin.
Mature virions which had been released from the cells were 
obtained by subjecting the supernatant from the first centrifugation 
to a second centrifugation at 12000rpm for 2.5h. This precipitate was 
resuspended in phosphate buffer and layered onto a linear gradient of 
15-40% sucrose in SW28 centrifuge tubes. After centrifugation at 
20000rpm in a SW28 rotor for lhr at 4°C, the band of virions was 
harvested using a syringe needle (21G) inserted through the tube.
Urea was added to a concentration of 0. 5M and the solution was 
sonicated in a sonicator bath (Kerry Pulsitron 55) for 5-10sec to
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facilitate the release of the virions from any cellular material. A 
weight of sucrose equal to that of the solution containing the virions 
was added to give a 50% w/w solution. A sucrose step-gradient was 
then constructed by layering 40% and 30% sucrose solutions upon the 
50% sucrose containing the virions. After centrifugation at 25000rpm 
for 18h in a SW28 rotor at 4°C, the band of virions was harvested 
again as above. The virions were diluted at least 2-fold in phosphate 
buffer and precipitated by centrifugation at 40000rpm for 18h at 4°C 
in a Ti50 rotor. This precipitate was then resuspended in a minimum 
volume of phosphate buffer (50-200pl>,
Mature virions and nuclear capsids were isolated from the 
sedimented cells. The cells were washed 2-3 times in PBS (Methods
8. 2) and resuspended in an equal volume of the hypotonic phosphate 
buffer. After leaving for lOmin for the cells to swell, they were 
homogenised with 20 strokes in a teflon/glass homogeniser. This was 
then subjected to centrifugation at 2000rpm for lOmin to sediment the 
nuclei. Virions were isolated from the supernatant using two sucrose 
gradients as described above.
Nucleocapslds were isolated from the sedimented nuclei. These 
were washed twice in PBS (Methods 8.2) and resuspended in Tris buffer. 
SDS was added to a final concentration of 0.5% and DNase I was added 
to give a final concentration of 50pg/ml and the mixture was incubated 
for lOmin at 25°C. Brij 58 was then added to a final concentration of 
0.5% and urea was added to give a concentration of 0. 5M. This mixture 
was then subjected to centrifugation at 2000rpm for lOmin and the
- 65 -
supernatant collected. Nucleocapslds were Isolated from the 
supernatant in a manner similar to that described above using the two 
sucrose gradient steps.
7. 2 Extraction of protein kinase activity from PRV Virions
Method 1 : A suspension of virions, to which 10% NP-40 was added to 
give a final concentration of 1%, was incubated at 25°C for 30min and
then subjected to centrifugation in a microfuge at 13000rpm for 5min.
The precipitate was resuspended in lOmM Tris-HCl pH7. 5 to restore the 
original volume. (Lemaster & Roizman, 1980)
Method 2 : 1M NaCl was added to a suspension of virions to give a
final concentration of 0.6M and NP-40 was added to give a
concentration of 10%. This was incubated for 30min at 25°C and then 
diluted 10-fold with lOmM Tris-HCl pH7. 5 before centrifugation and 
resuspension as for method 1. (Stevely et al., 1985)
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8. Assay and Isolation of PRV-PK
8. 1 Protein kinase assay (using protamine as substrate)
ATP mixture: The appropriate volumes of 1M MgCl2 and 5mM ATP were 
mixed to give lOmM MgCl2 and 0. 05mM ATP as final concentrations in the 
assay. 0. 5-2}iCi yC3:2P]ATP were added per assay to give a specific 
activity of 0. 08-0. 33jiCi/nM.
Substrate mixture: The appropriate volumes of 1M Tris-HCl pH 7. 5, 
2M KC1, 2-mercaptoethanol and lOmg/ml protamine sulphate were mixed to 
give 20mM Tris-HCl pH7. 5, 50mM KC1, 1% v/v 2-mercaptoethanol and 
0. 8mg/ml protamine sulphate as final concentrations in the assay.
10% w/w trichloroacetic acid in H20
5% w/w trichloroacetic acid in H20
40pl of the material to be assayed for enzyme activity were 
incubated with 20jxl ATP mixture and 60pl substrate mixture for 30min 
at 30°C. All the reaction mixture was then spotted onto Whatman 3MM 
filter discs which were then dropped into 10% trichloroacetic acid 
(10ml per filter). The filters were washed once with 10% 
trichloroacetic acid, twice with 5% trichloroacetic acid and once with 
ethanol, for 15min each. All the washings with trichloroacetic acid 
were performed at 4°C. The radioactivity was then measured as 
Cherenkov radiation in a scintillation spectrometer.
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8.2 Isolation of viral PRV-PK (Purvea et al.t 1987a)
PBS-A : lOg NaCl, 0. 25g KC1, 1. 44g Na2HP04, 0. 25g KH2P0A
In 11 water, pH adjusted to 7.4 with concentrated HC1
PBS-B : 0. 25g CaCl2 in 11 water 
PBS-C : 0. 25g MgCl2 in 11 water 
PBS : 8:1:1 mixture of PBS-A:PBS-B: PBS-C 
RSBE : lOmM KC1, 1. 5mM magnesium acetate, ImM EGTA,
lOmM Tris-HCl pH7. 5 
Med K : 25mM Tris-HCl pH7. 5, 125mM KC1, 5mM magnesium acetate,
5mM 2-mercaptoethanol 
PMSF : 20mg/ml in ethanol
buffer A : 20mM Tris-HCl pH7. 5, ImM EDTA, ImM EGTA, 
lOmM 2-mercaptoethanol, 10% glycerol 
buffer B : 1M ammonium sulphate in buffer A
a) Preparation of poat-rlbosomal supernatants from Infected and 
uninfected BHK cells
The cells were harvested by scraping them into the medium 
followed by centrifugation for lOmin at 2000 rpm. The sedimented 
cells were then washed twice with PBS, before resuspending in an equal 
volume of RSBE + 40pg/ml PMSF. After leaving on ice for 5min, the 
cells were homogenised with 20 strokes in a glass-teflon homogeniser.
0. 11 volumes Med K xlO were added and the cell debris removed by 
centrifugation at lOOOOrpm for 30min. This supernatant was further 
centrifuged for 2. 5h at 40000rpm in a Ti50 rotor at 4°C to sediment 
the ribosomes.
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b) DEAE-cellulose chromatography of protein kinases in post-ribosomal 
supernatants from tissue culture cells
The post-ribosomal supernatant was dialysed overnight against 
buffer A + 40p.g/ml PMSF.
i) Analytical Chromatography
A 1 x 5cm column of DEAE-cellulose (DE-52) was set up and 
equilibrated with buffer A. The flow rate was 12ml/h. A post- 
ribosomal supernatant prepared from cells harvested from 4-6 roller 
bottles was loaded at 12ml/h, and the column was washed with 12ml 
buffer A. Elution was then performed with a 60ml gradient of 0 - 0. 4M 
KC1 in buffer A. 60 fractions of lml were collected.
ii> Preparative Chromatography
This was performed as for analytical chromatography but using a 
column of 1. 6 x 6cm and a flow rate of 80-90ml/h. A post-ribosomal 
supernatant prepared from cells harvested from 30-40 roller bottles 
was loaded onto the column which was washed with buffer A. Protein 
was eluted with a similar 500ml gradient, and 70 fractions of 7ml 
collected. The fractions containing PRV-PK activity were stored 
at -70°C until the next stage of the purification.
c) Hydrophobic-interaction chromatography on TSK phenyl-5PW
The material from six DEAE-cellulose preparations (derived from
4-5 x 1010 infected cells) was allowed to thaw at 4°C and concentrated 
10-15 times in Aquacide II over 36h. The concentrated material was 
dialysed for 12h against several changes of buffer B. The dialysed
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material (35-40ral containing 90-100mg protein) was applied by repeated 
injection to a 7. 5 x 0. 75-cm TSK phenyl-5PW column, pre-equilibrated 
with buffer B, and linked to an HPLC system. The column was washed at 
tml/min with buffer B until all unbound protein had eluted, and then 
eluted with 60ml of a linear gradient of 1. 0 - 0M ammonium sulphate in 
buffer A lacking glycerol, at a flow rate of lml/min, and then with a 
further 20ml of the buffer at the final concentration of 0M ammonium 
sulphate. Fractions (1ml) were collected, and those containing PRV-PK 
were combined and subjected immediately to the next stage of the 
purification.
d) Threonine-Sepharose chromatography
L-threonine was coupled to AH-Sepharose-4B essentially according 
to Kikkawa et al. (1986), care being taken to maintain the pH between 
5 and 6 during the coupling reaction. After extensive washing with 
distilled water, a 7 x 1cm column of the chromedium was prepared and 
equilibrated with buffer A. The PRV-PK from TSK phenyl-5PW (20-25 ml 
containing 5-6mg protein) was applied directly (ie. without dialysis) 
to the column which was washed with 25ml buffer A at a flow rate of 
30ml/h, 5ml fractions being collected. The flow rate was then 
decreased to 15ml/h and the column eluted with 50ml of a linear 
gradient of 0 - 0. 4M KC1, followed by 25ml 0. 4M KC1, all in buffer A. 
PRV-PK was then eluted from the column with 50ml of a linear gradient 
of 0. 4 - 1. 0M KC1 in buffer A, 2. 5ml fractions being collected.
Finally, the column was washed with 15ml 1. 0M KC1. The fractions 
containing the bulk of the enzyme activity eluted at approximately 
0. 7M KC1. They were then combined and diluted with an equal volume of
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buffer A to decrease the ionic strength to a value which would allow 
immediate further chromatography without prior dialysis,
e> Protamine-agarose chromatography
The diluted PRV-PK (25-30ral containing 0.7-0. 8mg protein) was 
applied to a 3 x 1cm column of protamine-agarose, pre-equilibrated 
with buffer A. After washing with 20ml buffer A, the column was 
eluted with 12-ml steps of 0. 5M, 0. 8M and 1. 0M KC1 at a flow rate of 
12ml/h, 1.2ml fractions being collected. PRV-PK eluted at 0.8M. The 
fractions containing PRV-PK were stored at -70°C.
f) The specific activity of the final material from the purification 
of PRV-PK
This was calculated for the major peak of the purified enzyme.
The specific activity of y^32P^ATP in a standard assay was lpCi/12nmol 
ATP. lOOOcpm is equivalent to 1. 4nCi. In a standard assay, 40pl of 
this fraction (0. 8pg protein) gave 2.6 x 10scpm in a 30min incubation. 
This is equivalent to 0. 36pCi, which is equivalent to the 
incorporation of 4. 3nmol phosphate. Since 1 unit of enzyme activity 
is defined as that which produces lnmol phosphate in lmin, this is 
0. 14 units. The specific activity is thus 180 units/mg. This is one- 
fifth of the best results obtained by Purves et al. (1987a), but is 
comparable with the results obtained in other preparations of the 
enzyme. The lower value is probably due to greater inactivation of 
the enzyme during the preparation. Also, the measurement of the 
amount of protein at such low concentrations is not very accurate and 
could easily be out by a factor of two.
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9. Phosphorylation of viral proteins
9. 1 Phosphorylation of viral structural proteins In vitro
a) Endogenous protein kinase activity
This was carried out by incubating virions in the standard kinase
assay (Methods 8. 1) but in the absence of protamine and using 2pCi 
yt32P3ATP per assay which gives a specific activity of ljxCi/nM.
b) Exogenous protein kinase activity
Endogenous virion protein kinases were inactivated by incubation 
of virions at 85°C for 3min. This material was used as a substrate in 
the standard kinase assay as above (Methods 9. la) with various 
exogenous protein kinases.
The reactions were stopped by adding 50pl sample loading buffer
(Methods 4.2) and boiling for 3min. The samples were then ready for
electrophoresis (Methods 4.2a).
9.2 Detection of the phosphorylation of proteins during infection of 
cells
G-MEM growth medium (Methods 5) without tryptose phosphate 
and containing 10% new-born calf serum
G-MEM growth medium (Methods 5) without tryptose phosphate and 
containing 1% new-born calf serum
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BSS xlO : 6. 8g NaCl, 0. 4g KC1, 0. 2g MgSO*, 0. Ug  NaH2PO*,
0. 39g CaCl2, 1.5ml phenol red in 100ml water (sterile)
ES xlO : 5. 4ml MEM amino acids without L-glutamine x50,
2.7ml MEM vitamins xlOO, 2.7ml L-glutamine xlOO,
6.0ml 0. 5M glucose, 13ml water (sterile) 
phosphate-free medium :
40. 5ml BSS xl, 6. 7ml ES xlO, 1. 6ml NaHC03,
0.5ml penicillin/streptomycin, 0.5ml new-born calf 
serum, 5.5ml G-MEM growth medium without tryptose 
phosphate with 1% new-born calf serum 
urea lysis buffer : 9.8M urea, 2% NP-40, 1% 2-mercaptoethanol,
Two 25cm:2 flasks were seeded with 10s BHK cells which were allowed to
grow until approximately 80% confluent in G-MEM growth medium
(Methods 5) containing 10% new-born calf serum but without tryptose 
phosphate. They were then infected with 3 x 107pfu per flask 
(20pfu/cell) in G-MEM growth medium (Methods 5) containing 1% new-born 
calf serum but without tryptose phosphate for up to 24h. One hour 
before the period desired for adding C3aP]orthophosphate, this medium 
was replaced with 5ral phosphate-free medium, t32P]orthophosphate 
(0. 3-lmCi/flask) was added to the cells and the incubation continued 
for a further 3-12h.
a) Preparation of extracts from infected cells
The cells were harvested by pouring off the medium and scraping 
the cells into PBS (Methods 8.2). The cells were sedimented by 
centrifugation in a microfuge for 5min at 13000rpm and washed three
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times with PBS. They were then resuspended in urea lysis buffer which 
brought about lysis of the cells. The lysate was then centrifuged 
again for 30sec in a microfuge to sediment the nuclear material. The 
resulting supernatant was then mixed with sample loading buffer 
(Methods 4.2) and boiled for 3rain. This could then be subjected to 
polyacrylamide gel electrophoresis (Methods 4.2a).
b> Preparation of virions from the medium of infected cells
The medium was poured from the cells and subjected to 
centrifugation at 2000rpm for lOmin to sediment contaminating cellular 
material. The supernatant was then subjected to centrifugation in a 
Ti50 rotor at 40000rpm for 2.5h to precipitate the virions. The 
precipitate was then dissolved in sample loading buffer (Methods 4.2) 
and boiled for 3min. This could then be subjected to polyacrylamide 
gel electrophoresis (Methods 4.2a).
9.3 Preparation of autoradiographs
Gels containing radioactive material were stained for protein 
with Coomassie Blue (Methods 4. 2a) and then dried onto filter paper 
using a gel drier. The dried gel was then exposed to Fuji X-ray film 
for upto one week before developing the film. Rainbow protein 
molecular weight markers were used. After the gel had been dried, the 
positions of the molecular weight markers were marked on the gel with 
radioactive ink so that their position could be seen on the 
autoradiograph.
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10. Preparation of 0-galactoaldase fusion-protein for Injection into 
rabbits for the preparation of specific anti-sera
10. 1 Expression of 0-galactosldase fusion-protein in E. coli
40ral L-broth + ampicillin (Methods 1) were inoculated with 2ml 
overnight culture of £. coll transformed with the relevant plasmid 
(Results A. 1) and incubated at 30°C for 5h, before inducing the 
expression of the fusion-protein by increasing the temperature to 42°C 
for 2h.
10.2 Preparation of E. coll protein extract
The cells were harvested by centrifuging for lOmin at lOOOOrpm, 
and resuspended in 4ml 0. 3M NaCl, 50mM Tris-HCl pH7. 5, ImM EDTA.
0.4ml 40mg/ml H20 lysozyme was added and incubated for lOmin on ice 
before adding 40pl 10% v/v NP-40 in H20 for a further lOmin. This was 
then centrifuged in a microfuge for lOmin and the precipitate 
resuspended in 4ml 5% w/v SDS, 1% v/v 2-mercaptoethanol in H20. It 
was found necessary to boil this for 5-10min in order to dissolve all 
the protein.
10. 3 Partial purification of the fusion-protein by Sephacryl S300 
chromatography
A Sephacryl S300 column <50xlcm> was equilibrated with running 
buffer (5% SDS, 0. 1M NaCl, lOmM Tris-HCl pH7. 5) and run at a flow rate 
of 20ml/h at room temperature. tml samples of E. coli extract were 
loaded onto the column and 50 fractions of 1ml were collected.
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Fractions were analysed for protein by measuring the A=lso. Those 
corresponding to the first peak were then subjected to polyacrylamide 
gel electrophoresis in order to determine the purity of the fusion- 
protein. Fractions having sufficient purity (Results A. 2) were pooled 
and dialysed against 31 lOmM Tris-HCl pH7 twice, in order to remove as 
much of the SDS as possible. The protein was then precipitated with 
acetone (Methods 4.2c) and redissolved in 0.5ml lOmM Tris-HCl pH7.
10.4 Injection of fusion-protein into rabbits
1st injection: lmg fusion-protein in a volume of 0.5ml was mixed 
with an equal volume of Freund’s complete adjuvant by sonication, and 
injected subcutaneously at 4 sites.
2nd injection: after 5 weeks, a further lmg of the fusion-protein 
was similarly injected after mixing with an equal volume of Freund's 
incomplete adjuvant.
Further injections were carried out as for the second injection 
at 2-3 monthly intervals.
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11. Preparation of Anti-sera
11. 1 Bleeding of rabbits
Rabbits were bled 10 days after each injection, except for the 
first one, and also at approximately monthly intervals. 20ml of blood 
v was collected each time from the ear vein.
11.2 Preparation of anti-serum
20ml blood was left to clot for 2h at 4°C in a glass container. 
The serum was collected from round the clot and centrifuged for 15min 
at lOOOOrpm. The supernatant was collected and added to 6g DEAE- 
cellulose (Whatman DE-52) which had been equilibrated overnight in 
phosphate buffer (lOmM KH2P0.4./K2HP0A pH7. 5). The supernatant was left 
for 30min on ice with occasional stirring before removing the DEAE- 
cellulose by filtration. The filtrate was then diluted 1: 1 with 
phosphate buffer before adding 25.8g/100ml solid (NH^sSO*, slowly 
with continual stirring for 15min, while on ice. The precipitate was 
sedimented by centrifugation for 15min at lOOOOrpm at 4°C. The pellet 
was redissolved in 2ml phosphate buffer and dialysed against two 
changes of phosphate buffer. The anti-serum was stored as lOOpl 
aliquots at -20°C.
11.3 Affinity-purification of anti-serum by elution from 
nitrocellulose filters
An extract containing the antigen against which the anti-serum 
was to be purified, was subjected to electrophoresis and transferred 
to a nitrocellulose filter (Methods 12). The nitrocellulose filter
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was blocked and incubated with the anti-serum as for an immunoblot 
(Methods 12). Strips were cut from either end of the nitrocellulose 
filter and incubated with a second antibody and the appropriate 
reaction solution in order to locate the antigen and hence the 
position of the desired antibody on the filter. A narrow strip 
corresponding to this region of the filter was cut out. The antibody 
was eluted by incubation for 2min in 1ml 0. 2M glycine pH2. 8,
0.2% gelatin. The filter was then removed and stored in PBS (Methods 
8.2) for further use, while 1M Tris base was added to the eluted 
antibody to give a pH of 7. 0. This antibody could then be used in 
immunoblots.
12. Immunoblotting
transfer buffer: 25mM Tris, 192mM glycine, 20% methanol,
0. 025% SDS
blocking buffer: 20mM Tris-HCl pH7. 2, 0. 15M NaCl, 0. 5% Tween 20
solution containing 1st antibody:
20ml blocking buffer, 1ml heat-inactivated 
horse serum, 40-200pl anti-serum (approximately 
20-100 fold dilution of serum) 
solution containing 2nd antibody 
peroxldase-coupled:
20mM Tris-HCl pH7.2, 0. 15M NaCl, 3% bovine 
serum albumin, lOpl/lOml horse radish 
peroxidase-coupled donkey anti-rabbit 
immunoglobulin G 
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alkaline phosphatase-coupled:
20mM Tris-HCl pH7.2, 0. 15M NaCl, 3% bovine 
serum albumin, 3pl/10ml alkaline phosphatase- 
coupled goat anti-rabbit immunoglobulin G
reaction solution
peroxidase: lOmg 4-chloro-l-napthol dissolved in 3ml cold 
methanol C-20°C) + 15ml blocking buffer without 
Tween 20
alkaline phosphatase: 10ml 0. 1M Tris-HCl pH9. 5, 0. 1M NaCl,
5mM MgCl2, plus 66pl 50mg/ml Nitro Blue 
Tetrazoliura in 70% dimethylformamide plus 
33pl 50mg/ml 5-brorao-4-chloro-3-indolyl phosphate 
in dimethylformamide
Protein samples were subjected to polyacrylamide gel 
electrophoresis (Methods 4.2a). Amersham pre-stained Rainbow 
molecular weight markers were used as molecular weight standards.
The gel was 'blotted' onto a nitrocellulose filter as follows: 
the gel was placed in a sandwich between one sheet of 3MM filter paper 
and a nitrocellulose filter. A further piece of 3MM filter paper was 
placed upon the nitrocellulose filter. This sandwich was placed in an 
electrophoretic transfer tank with transfer buffer. The transfer was 
performed overnight at 60mA or for 6h at 350mA. After the transfer 
had been performed, the pre-stained molecular weight markers could be 
seen on the nitrocellulose filter. However, they were found to fade 
considerably during the course of the subsequent incubations of the 
filter. Therefore, to avoid losing the positions of the markers,
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these were marked with a biro at this stage before commencing the 
incubations.
The nitrocellulose filter was incubated with approximately 50ml 
blocking buffer for l-2h and then with the first antibody for 5-24h at 
room temperature with gentle shaking. In many cases it was necessary 
to cut the filters at this stage, either to allow different parts of 
the filters to be incubated with different anti-sera, or to minimise 
the volume of the first anti-serum required for the incubation.
Filters were subsequently stuck together for photographing, but the 
cut-lines remain visible as fine lines in the photographs. The first 
antibody was poured off and the nitrocellulose filter washed twice 
with 50ml blocking buffer (lOmin each wash) and once with water. The 
nitrocellulose filter was incubated for a further 5-24h with the 
second antibody. After washing as before, the nitrocellulose filter 
was put in the appropriate reaction solution. The reactions were 
stopped by washing the filters with H20.
The first antibody was reused for many blots until the reaction 
became significantly weaker. The second antibody was not reused.
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Chapter 3 
RESULTS
A
Studies with antibodies
It was decided to use an immunochemical approach to determine the 
relationship between the putative protein kinase gene, pk, and PRV-PK, 
and to investigate the distribution of the product of this gene. The 
first step was to raise anti-sera against the protein products of the 
US3 gene of HSV-1 and the pk gene of PRV. In order to do this, 
fragments of both of these genes were expressed as fusion-proteins in 
F. coll and the resulting fusion-proteins were injected into rabbits to 
raise anti-sera which could cross-react with the products of these 
viral genes.
A. 1 Construction of recombinants for the expression of fusion-proteins
Constructs were made in the expression vector, pUEX-1 (fig 3.la). 
This is one of a series of vectors, (pUEX-1, 2 and 3 : Materials 6) 
which allows a fragment of DNA to be expressed in E. coli as a fusion- 
protein with p-galactosidase (Bressan & Stanley, 1987). The fragment 
to be expressed is cloned into one of five unique restriction sites 
located at the 3' end of the coding region of the lac z gene. The 
resulting protein thus consists of llOkDa of p-galactosidase, to the 
C-terminus of which, the foreign protein is fused. The three vectors 
of this series differ in the precise positions of the unique
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restriction sites, so that by choosing the correct vector, the 
fragment of DNA can be expressed in the correct reading frame, if this 
is known.
The recombinant, pUEX-P, was constructed in order to express part 
of the pk gene of PRV as a fusion-protein with p-galactosidase. From 
knowledge of the nucleotide sequence and predicted reading frame of 
the pk gene, it was decided to clone a 0. 8kb Pst I fragment of this 
gene, cut from the plasmid, pPRVB 10 (Materials 6 : fig 3. lb), into 
the Pst I site of pUEX-1. This fragment includes most of the coding 
region of the pk gene (amino acids 49-334), and also the translation 
termination codon.
The orientations of the resulting clones were distinguished by 
restriction digestion with Bam HI. From the restriction maps 
(fig 3. lb) it can be seen that the desired orientation should yield 
fragments of 0. 8kb and 6. 7kb, and the other orientation should produce 
fragments of 0. 03kb and 7. 5kb. Figure 3.2a lane 1 shows that the 
clone selected yielded fragments of 0.8kb and 6.7kb, indicating that 
it had the correct orientation. This clone was designated pUEX-P.
The recombinant, pUEX-S, was constructed similarly in order to 
express part of the US3 gene of HSV-1. From knowledge of the 
nucleotide sequence and predicted reading frame of the HSV-1 US3 gene, 
it was decided to clone a 0. 8kb Sal I fragment, cut from the plasmid 
pRB 425 (Materials 6 : fig 3. lc), into the Sal I site of pUEX-1. This 
should encode a fusion-protein of 140kDa which includes most of the 
kinase domain of the US3 gene product (amino acids 97-363). Since 
this fragment does not include a translation termination codon, 
termination of translation of the fusion-protein should occur at one
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of the termination codons present at the C-terminus of lac z in the 
vector.
The 0. 8kb Sal I fragment was cloned into pUEX-l and two products, 
which proved to be the two different orientations, were obtained. 
Restriction digestion with Bam HI was used to distinguish between the 
two orientations. The restriction map (fig 3. 1c) indicates that the 
desired orientation should yield fragments of 0.8kb and 6.7kb, while 
the other orientation should produce fragments of 0.03kb and 7. 5kb. 
Figure 3.2b lane 2 shows the clone which yielded fragments of 0. 8kb 
and 6. 7kb, indicating that it has the desired orientation. This clone 
was designated pUEX-S.
A. 2 Expression and partial purification of fusion-proteins
The pUEX vectors express the fusion-protein from the cro promoter 
of the bacterial phage lambda. This promoter is repressed by the kcl 
repressor. The vector contains the gene encoding a temperature- 
sensitive mutant of this repressor, cl 857, which is still able to 
repress expression at the permissive temperature, 30°C, but not at the 
non-permissive temperature, 42°C.
Transformed E. coli containing the recombinant constructs were 
grown as described (Methods 10. 1). A time course of expression of the 
fusion-protein showed that the maximum amount was produced in 2h, and 
longer incubation periods did not increase the amount of fusion- 
protein produced (fig 3.3>.
The fusion-protein was produced as an insoluble aggregate. In 
order to solubilise this material for analysis by polyacrylamide gel
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electrophoresis, it was found necessary to boil the material in 
5% SDS, 2% 2-mercaptoethanol for 5-10 minutes. Use was made of the 
insolubility of the fusion-protein in the first step of a 
purification, by lysing the cells to release the soluble cytosolic 
proteins before solubilisation of the fusion-protein (Methods 10.2). 
The extract produced by the solubilisation of the aggregated material 
remaining after lysis of the cells was found to contain fewer proteins 
than the total extract (fig 3.4).
It is of interest to note that the fusion-protein expressed from 
pUEX-P consisted of one major species, whereas pUEX-S produced a 
fusion-protein with four major species with molecular weights of 
160000, 140000, 125000 and 120000 as estimated from polyacrylamide gel 
electrophoresis (fig 3.6). This was probably because termination of 
translation was more efficient in pUEX-P where it would be expected to 
have occurred at the termination codon of the pk gene. In pUEX-S, 
termination of translation at the artificial termination codon in the 
vector was probably less efficient, giving rise to multiple species.
Analysis of E. coli extracts by polyacrylamide gel electrophoresis 
showed that the fusion-protein was the major high molecular weight 
protein present in the extract. This suggested that partial 
purification could be achieved using gel filtration. Extracts were 
therefore subjected to chromatography on Sephacryl S300 (Methods 
10.3). The eluted protein was detected by measuring the Amo*
Aliquots from the column fractions were subjected to polyacrylamide 
gel electrophoresis. The fusion-protein eluted in the first fractions 
which contained protein (fig 3. 5 A 3.6), The material from the first 
one or two fractions of four such columns was pooled (fig 3.7a) and
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used for injection into a rabbit (Methods 10.4). Similar material was 
used for subsequent injections.
A. 3 Initial characterisation of anti-sera
The initial bleeds from each rabbit were tested in immunoblots 
(Methods 12) against extracts containing the partially purified 
fusion-proteins, in order to determine if antibodies had been raised 
against the material which had been injected into the rabbits.
Figure 3.7b shows immunoblots of anti-serum P (raised against the PRV 
fusion-protein) and anti-serum S (raised against the HSV fusion- 
protein) against pooled fractions from both Sephacryl S300 columns 
which contained the fusion-proteins (fig 3. 7a lanes 2 A 3).
Pre-immune serum from both rabbits was also tested against the fusion- 
proteins. No cross-reaction could be detected in the immunoblots with 
either pre-immune serum. However, anti-sera P and S were both found 
to react with a number of proteins in the partially purified fractions 
containing the fusion-proteins. These included several proteins with 
a high molecular weight (100000 to 160000) which could correspond to 
the fusion-proteins. The cross-reaction of anti-serum P with the HSV 
fusion-protein is probably due to antibodies against the 
P-galactosidase portion of the protein. This would also account for 
the cross—react ion of anti-serum S with the PRV fusion-protein. The 
anti-sera also reacted with other bacterial proteins present in the 
extracts containing the partially purified fusion-proteins.
Both anti-sera were then tested in immunoblots against post- 
ribosomal extracts (Methods 8.2a) from uninfected BHK cells, BHK cells
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infected with HSV-1 and BHK cells infected with PRV. Figure 3.8a 
shows an immunoblot of anti-serum P against post-ribosomal 
supernatants from BHK cells infected with PRV (lane 2) and uninfected 
BHK cells (lane 4). Although, in each extract, the anti—serum reacted 
with several proteins (a major cross-reacting species having a 
molecular weight of 34000 and a minor species with a molecular weight 
of 52000), there were two major bands, corresponding to molecular 
weights of 38000 and 42000, which were specific to the extract from 
infected cells, although in many preparations, of these two bands, 
only the 38000 molecular weight band was seen (eg. fig 3. lib lanes S>. 
This suggested that at least one of these proteins corresponds to the 
viral product of the pk gene of PRV. There were also a number of 
significantly fainter bands, detected only in the extract from 
infected cells, corresponding to lower molecular weight proteins. It 
was unclear if these were viral proteins or virally-induced cellular 
proteins, but they appeared to be either less abundant or the 
anti-serum exhibited a lower affinity for them, which suggested that 
they did not correspond to products of the pk gene.
Similarly, anti-serum S, although reacting with a number of 
proteins, recognised two proteins of 68kDa and 69kDa which were only 
present in extracts from cells infected with HSV-1. The reaction was 
rather weak in post-ribosomal supernatants from infected cells 
(result not shown), but was stronger in fractions from the first stage 
of purification of HSV-PK (DEAE-cellulose column fractions s 
fig 3.9 lane 2). Previous work (Frame et al., 1987) has identified 
HSV-PK as a 68kDa protein. However, it seems likely that both the 
68kDa and 69kDa proteins detected in the immunoblot with anti-serum S
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correspond to the protein kinase which is the product of the US3 gene 
of HSV-1.
In an immunoblot in which the same amount of protein (as in 
fig 3.9 lane 2) from the DEAE-cellulose stage of purification of 
HSV-PK was transferred to nitrocellulose and incubated with anti-serum 
P, no reaction was observed (fig 3.8b lane 2>. Similarly, when the 
same amount of a post-ribosomal extract from cells infected with PRV 
as in figure 3.8a lane 2, was transferred to nitrocellulose and 
incubated with anti-serum S, only a single band of approximately 34kDa 
(fig 3.9 lane 4), which was also present in an extract from uninfected 
cells (fig 3.9 lane 3) was detected. This suggests that the protein 
products of these two genes encoding protein kinases are not 
sufficiently closely related for either anti-serum to recognise both 
proteins.
B
The purification of PRV-PK and the determination of the relationship 
between this enzyme and the product of the pk gene of PRV.
In order to determine the relationship between the product of the 
pk gene of PRV, recognised by anti-serum P, and PRV-PK, the protein 
kinase which is induced in cells infected with PRV (Introduction C), 
the latter was purified to homogeneity, and immunoblotting was carried 
out using anti-serum P on fractions from all stages of the 
purification. PRV-PK was purified to homogeneity according to the
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method of Purves et al. (1987a) (Methods 8.2). This involved 
preparing a post-ribosomal supernatant from infected cells and 
subjecting this to chromatography on four columns successively; 
DEAE-cellulose, TSK phenyl-5PW, threonine-Sepharose and protamine- 
agarose. Figure 3. 10 shows the analysis of aliquots from each step of 
the purification by polyacrylamide gel electrophoresis. The silver- 
stained gel of the peak fractions from the protamine-agarose column 
shows that the protein has been purified to homogeneity.
Protein was eluted from the DEAE-cellulose column by applying a 
gradient of 0 - 0. 4M KC1 (Methods 8.2bii>. Assaying the fractions 
with protamine, revealed two major peaks of protamine kinase activity 
(fig 3. 11a). From previous work (Katan et al., 1985) the first peak 
of activity was identified as protein kinase C from the concentration 
of KC1 at which it eluted (0. 05M). Similarly, the second peak of 
activity was identified as PRV-PK from its elution at 0. 2M KC1. In 
immunoblots (fig 3.11b), using anti-serum P, fractions 40-44, which 
corresponded to the peak of the PRV-PK activity, were found to give a 
single positive reaction against a protein with the same molecular 
weight (38 000) as the major protein recognised by this anti-serum 
uniquely in extracts from cells infected with PRV (fig 3.8a lane 2). 
The intensity of the reaction corresponded to the amount of activity 
detected in the fractions. Fractions 20-24 also gave a positive 
reaction in immunoblots with this anti-serum (fig 3. lib). The 
molecular weight of the protein detected in these fractions was 34000, 
corresponding to that of the major cellular protein against which 
anti—serum P cross—reacted in extracts from uninfected cells 
(fig 3.8a lane 4). The different chromatographic properties of the
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34kDa and 38kDa proteins show that they are clearly distinct.
The fractions corresponding to the PRV-PK peak from six 
DEAE-cellulose columns were concentrated and loaded onto a TSK 
phenyl-5PW HPLC column, washed and the protein kinase activity eluted 
with a salt gradient of 1. 0 - 0. 0 M ammonium sulphate (Methods 8.2c). 
Four peaks of protamine kinase activity were detected (fig 3. 12 : 
corresponding to fractions 36-46, 48-54, 60-66 & 68-74), in contrast 
to the single peak eluting at 0M ammonium sulphate obtained in 
previous purifications (Purves et al., 1987a).
Fractions 37-44, 49-54 and 62-72 corresponding to all four 
apparent peaks of protein kinase activity were pooled and loaded onto 
the threonine-Sepharose column, although immunoblots with anti-serum P 
subsequently detected only the 38kDa protein in fractions 42-56 
(fig 3.12). Protein kinase activity was eluted with a salt gradient 
of 0 - 1.0M KC1 (Methods 8. 2d) as a single peak (fig 3.13) which did 
not coincide with the elution of most of the protein from the column. 
Immunoblot ting of fractions from the major peaks of protein and 
protein kinase activity eluted from the column, showed that anti-serum 
P reacted with a protein of 38kDa only in the fractions corresponding 
to the peak of protein kinase activity (fig 3.13). The intensity of 
the reaction on the immunoblot was related to the amount of protein 
kinase activity present in the fractions.
Fractions 55-62 from the threonine-Sepharose column were pooled 
and loaded onto a protamine-agarose column. After washing, the 
protein kinase activity was eluted with a salt gradient of 
0 - 1.0M KC1 (Methods 8. 2e) as two overlapping peaks, with the peak 
eluting at the higher salt concentration, corresponding to the
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position of elution observed in previous work (Purves et al. , 1987b: 
fig 3. 14). Analysis of the protein in the peak fractions by 
polyacrylamide gel electrophoresis and visualisation by silver 
staining showed that both peaks contained a single protein of 38kDa, 
corresponding to PRV-PK (fig 3. 10 lane 6a A 6b>. In immunoblots, 
anti-serum P gave a positive reaction against a protein of 38kDa in 
fractions from both peaks (fractions 30, 38 & 40 : fig 3.14), but the 
reaction was much more intense for the fractions corresponding to the 
second peak. It is unclear why the final preparation of PRV-PK in 
this purification should have eluted as two peaks, and this question 
is considered further in the Discussion.
From the foregoing, it can be concluded that anti-serum P 
specifically recognises the 38kDa protein kinase induced by infection 
with PRV (PRV-PK). Hence PRV-PK is encoded by the pk gene of PRV 
which corresponds to the US3 gene of HSV-1.
C
Location of PRV-PK and HSV-PK within virions
Although previous work (Katan et al., 1985) had indicated that 
PRV-PK is present in the soluble fraction from infected cells, it was 
intended to use anti-serum P in immunoflorescence studies to determine 
the location of PRV-PK more precisely in intact cells. However, since 
the anti-serum was found to cross-react with cellular proteins 
(Results A. 3), it was first necessary to affinity-purify the 
anti-serum against PRV-PK (Methods 11.3). Material from the
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TSK phenyl-5PW stage of the purification of the protein kinase was 
transferred to a nitrocellulose filter (Methods 12). Anti-serum P had 
been shown (fig 3. 12) to react with a single protein of 38kDa in this 
material. After incubating the nitrocellulose filter with anti-serum 
P, the position of the 38kDa protein was located and a strip 
corresponding to this part of the nitrocellulose filter was cut out. 
Antibodies were eluted from this (Methods 11.3) and used in an 
immunoblot against post-ribosomal extracts and material from the 
DEAE-cellulose stage of the purification of the protein kinase. These 
antibodies were found to react with the 38kDa protein, but also with 
the 34kDa cellular protein (fig 3. 15a). This suggests that these two 
proteins are antigenically related and are reacting with the same 
antibodies in the anti-serum. This was confirmed in a similar manner 
by affinity-purifying antibodies against the 34kDa protein. The 
material transferred to a nitrocellulose filter in this case was from 
fractions of the DEAE-cellulose column where the 34kDa protein was 
found to elute (fig 3.lib) and which did not contain the 38kDa 
protein. Antibodies eluted from the 34kDa band on the immunoblot 
(fig 3. 15b lane 2) also reacted with the 38kDa protein 
(fig 3. 15b lane 1). Thus, anti-serum P, even after affinity- 
purification, cross-reacted with a cellular protein and hence was 
unsuitable for immunoflorescence studies.
Nevertheless, this anti-serum was suitable for investigating the 
location of PRV-PK within PRV virions, using immunoblotting. Mature 
PRV virions were isolated from the cellular growth medium after 
infection for 20-24h (Methods 6.2 & 7.1). Figure 3.16a lane la shows 
the analysis of the resulting material by polyacrylamide gel
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electrophoresis. The detection of proteins of molecular weight 
greater than 200kDa indicated the presence of tegument proteins and 
suggested that the virions were mature. The immunoblot using 
anti-serum P (fig 3. 16a lane 5) against this material gave a single 
positive reaction against a protein of 38kDa. This indicated that 
PRV-PK was present in mature PRV virions.
Having shown that PRV-PK is present within PRV virions, studies 
were carried out to investigate the location of the enzyme within the 
virions more precisely. Nucleocapsids (ie. immature virions 
consisting of only the inner two layers of the virion) were isolated 
(Methods 7. 1) from the nuclei of infected cells, where they accumulate 
before acquiring the envelope by budding through the nuclear membrane. 
In immunoblots with anti-serum P (fig 3.16a lane 4), this material 
also gave a single positive reaction against a protein of 38kDa, 
suggesting that PRV-PK is tightly associated with the nucleocapsid, 
although the possibility remains that the nucleocapsid preparation may 
have been contaminated by PRV-PK present in the cytosol of the 
infected cells.
Similar experiments were carried out to investigate the location 
of HSV-PK within HSV-1 virions. Mature virions were isolated from 
cellular growth medium (as for PRV, Methods 7.1), after infection for 
20-24h with HSV-1 (as for PRV, Methods 6.2). Nucleocapsids were also 
isolated from the nuclei of these cells (as for PRV, Methods 7.1). 
Immunoblots against both nucleocapsids and mature virions using 
anti—serum S yielded two bands of 68kDa and 69kDa, similar to those in 
immunoblots against fractions from the DEAE-cellulose stage of 
purification of HSV-PK (fig 3. 17). Thus this protein kinase is also
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present within the virion and is probably tightly associated with the 
nucleocapsid.
The location of PRV-PK within PRV virions was further 
investigated by the treatment of virions with either 1% NP-40 
(Methods 7.2), which was used by Lemaster et al. (1980) to solubilise 
virion envelope proteins, or 10% NP-40, 6M NaCl (Methods 7.2> which 
was used by Stevely et al, (1985) to solubilise protein kinase 
activity from PRV virions. In an experiment using both methods, 35% 
of the protamine kinase activity within PRV virions was solubilised. 
Immunoblots were performed using equivalent amounts (ie. derived from 
the same number of virions) of the solubilised material and the 
material which remained insoluble from both methods of extraction 
(fig 3. 16b). The difference in intensity of the reaction with anti­
serum P for the solubilised and insoluble material showed that PRV-PK 
is not efficiently solubilised under either of these conditions, 
suggesting that the protein kinase solubilised by these treatments was 
protein kinase C. The fact that neither of these methods efficiently 
solubilised PRV-PK supports the hypothesis that PRV-PK is tightly 
associated with the nucleocapsid of the virion.
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DThe phosphorylation of viral structural proteins of PRV in vitro and 
In vivo
Having established that PRV-PK is present within PRV virions, 
experiments were performed to see if PRV-PK might have a role in the 
phosphorylation of virion proteins during infection.
First, the virion proteins phosphorylated in vivo were examined 
by incubating the cells with Ca2P]orthophosphate during infection with 
PRV. Extracts were prepared from cells 15h after infection in the 
presence of CaaP]orthophosphate from 12-15h (Methods 9.2a). An 
extract was also prepared from mock-infected cells which had similarly 
been incubated with C 3:2P] orthophosphate for 3h. Figure 3. 18a shows an 
autoradiograph of these extracts. Extracts from mock-infected cells 
(fig 3. 18a lanes 4 & 5) contained many more phosphoproteins, 
suggesting that viral infection inhibits the phosphorylations of 
cellular proteins. However, the extracts from infected cells 
contained five phosphoproteins of 210kDa, 112kDa, 43kDa and two of 
approximately 52kDa, which appeared to be induced by infection 
(fig 3. 18a lane 2 & 3).
In order to investigate whether these virally-induced 
phosphoproteins were viral structural proteins, a crude preparation of 
virions was prepared from the growth medium of cells incubated with 
[ ^ P] orthophosphate from 4-24h after infection (Methods 9.2b). A 
longer labelling period was used in this experiment in order to allow 
the virion proteins labelled in the cytosol to be incorporated into
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virions and released into the medium. As a control, a similar 
preparation was made from mock-infected cells. Figure 3. 18b 
lane 1 & 2 shows that four major phosphoproteins of 112kDa, 32kDa and 
two of approximately 52kDa were detected in this virion preparation.
A phosphoprotein of approximately 52kDa was also detected in the 
preparation from uninfected cells (fig 3. 18c lane 2), indicating that 
one of the phosphoproteins of this molecular weight may be a cellular 
protein. However the detection of phosphoproteins of 112kDa and 52kDa 
in this preparation suggests that at least these two of the five 
phosphoproteins detected in infected cells are viral structural 
proteins.
The possible role of PRV-PK in the phosphorylation of these viral 
structural proteins was then investigated by studying the ability of 
this enzyme to phosphorylate virion proteins in vitro. Virions in 
which the endogenous protein kinase activity had been inactivated by 
heat, were incubated with purified PRV-PK in the presence of yC^PDATP 
(Methods 9. lb). Under these conditions, four major phosphoproteins 
were observed with molecular weights of 112000, 56000, 38000 and 32000 
(fig 3. 19 lane 6). The 38kDa phosphoprotein was identified (from 
fig 3. 19 lane 5, which corresponds to the incubation of purified PRV- 
PK with vt3aP3ATP in the absence of virions) as being PRV-PK, having 
undergone autophosphorylation. However, the identity of the 32kDa and 
56kDa proteins is unknown, although it is possible that the 32kDa 
protein corresponds to the phosphoprotein of this size detected in 
virions which were labelled in vivo (fig 3. 18b lane 1). The 112kDa 
protein, which was also phosphorylated in vivot appears to be the 
major substrate for PRV-PK in vitro. This is one of the major
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proteins of PRV virions (fig 3.16a lane la) and has been shown here 
(fig 3. 19 lane 2) and in previous work (Stevely et al. , 1985) to be •
phosphorylated by the cellular protein kinase, casein kinase II. It
was also found to be a substrate for cAMP-dependent protein kinase
(fig 3. 19 lane 4). However, studies on the substrate specificities of
these protein kinases using peptides as substrates (Purves et a l . ,  
1986a; Marin et al . , 1986) suggest that it is unlikely that they all 
phosphorylate the same site(s) on the 112kDa protein.
It was also of interest to examine the phosphorylation of virion 
proteins by the endogenous protein kinases in situ by incubating 
mature virions or nucleocapsids with y[3aPlATP (Methods 9.1a). In 
nucleocapsids, the major phosphoprotein had a molecular weight of 
58000 (fig 3.20 lane 5). Since the phosphorylation of this protein 
was not detected when heat-inactivated nucleocapsids were incubated 
with exogenous PRV-PK (fig 3.20 lane 3), it is suggested that this 
protein is phosphorylated by another protein kinase. The other 
phosphoproteins of 112kDa, 38kDa and 32kDa may correspond to _those 
phosphorylated by PRV-PK in heat-inactivated mature virions 
(fig 3. 19 lane 6), and hence be substrates for PRV-PK. In mature 
virions, one major phosphoprotein of 112kDa and three other highly 
phosphorylated proteins of 56kDa, 38kDa and 32kDa were detected along 
with several minor phosphoproteins (fig 3. 19 lane 8a & b). This 
pattern of phosphorylation appeared to be similar to that obtained by 
the incubation of exogenous PRV-PK with heat-inactivated virions 
(fig 3. 19 lane 6), suggesting that PRV-PK may be responsible for these 
phosphorylations. However, previous work (Stevely et al . , 1985)
showed that the PRV virion contains at least four protein kinase
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activities, including casein kinase II, which was also able to 
phosphorylate the 112kDa protein.
In order to determine whether PRV-PK as well as casein kinase II 
contributed to the endogenous phosphorylation of this protein, the 
effect of the protein kinase inhibitors, heparin and polyarginine, 
were investigated. The efficiency and specificity of inhibition was 
initially tested on crude preparations of PRV-PK and casein kinase II. 
PRV-PK was inhibited 12% by lpg/ml heparin and 85% by 0.5mg/ml 
polyarginine, whereas casein kinase II was inhibited 82% by ipg/ml 
heparin and 45% by 0. 5mg/ml polyarginine. However, although heparin 
is an effective inhibitor of casein kinase II and polyarginine is an 
effective inhibitor of PRV-PK, when used at these concentrations, 
neither inhibitor was found to inhibit the phosphorylation of PRV 
virion proteins by the endogenous protein kinases in vitro 
(fig 3.21a lane 3, fig 3.21b lane 2). This lack of inhibition may 
result from the inaccessibility of the protein kinases within the 
virions to the inhibitors. Alternatively it may be one of the other 
endogenous protein kinases which is responsible for the observed 
phosphorylations. The effect of 0.5M KC1 on endogenous 
phosphorylation was also investigated. It was found in a preliminary 
experiment that PRV-PK is not inhibited at 0. 5M KC1, although this 
concentration of KC1 inhibited casein kinase II by 91%. When 0. 5M KC1 
was included in the reaction mixture, it was found to significantly 
inhibit the phosphorylation of all the proteins observed to be 
phosphorylated by the endogenous protein kinase activities 
(fig 3.21a lane 2), thus implying that PRV-PK does not play a major 
role in these reactions. From these results it would appear that, in
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vitro, the phosphorylation of the 112kDa protein is catalysed by 
another enzyme, probably casein kinase II, rather than PRV-PK.
However, it cannot be excluded that in vivo, PRV-PK might contribute 
to the phosphorylation of this protein , perhaps during assembly.
E
Attempt to express the US3 gene of HSV-1 in eukaryotic cells.
It was intended to express the US3 gene of HSV-1, in a eukaryotic 
cell line, with the initial aim of investigating possible 
physiological substrates for this enzyme, in particular, whether there 
are any cellular substrates. A comparison of the pattern of 
phosphorylation in cells with and without the enzyme should allow the 
identification of a possible cellular substrate. A second aim was to 
investigate whether the expression or over-expression of this protein 
kinase gene could cause malignant transformation of the cells, as had
been observed for protein kinase C (Housey, et al,, 1988;
Persons et al., 1988) and oncogenic tyrosine kinases, such as src 
(Johnson et al., 1985), or cause any other changes in the phenotype of 
the cells. In addition, the ovei— expression of the gene could provide 
a plentiful supply of active protein kinase for various studies of the 
enzyme.
The vector Homer 5 (Spandidos & Anderson, 1987) was chosen for 
this work. This vector Is designed to express a eukaryotic gene from 
its own promoter, but expression is enhanced by the presence of the
enhancer sequence from SV40 which is located beside the unique
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Hind III site into which the gene is to be cloned (fig 3.23a). The 
orientation of the gene relative to the SV40 enhancer is thought to be 
unimportant (Spandidos & Anderson, 1987). The vector also contains 
the ampicillin resistance gene for selection of transformants during 
cloning in E. coll, and the geneticin resistance gene to allow the 
selection of eukaryotic transformants.
Since one of the aims of the work was to investigate whether the 
expression of this gene could cause malignant transformation, the cell 
line chosen for transformation, the rat fibroblast cell line, 208F, 
was one known to have a low frequency of spontaneous malignant 
transformation (Quade, 1979).
E. 1 Construction of the plasmids, transformation of recombinants into 
208F cells and selection of transformants.
The fragment of the US3 gene chosen was one of 2.8kb, flanked by 
Kpn I and Sph I sites (see fig 3.22b). This includes the promoter for 
the US3 gene and the information for the complete mRNA transcript. 
Since the transcripts for US3 and US4 are co-terminal, the entire 
coding region for the US4 gene would also be present in a construct 
including this fragment. As a control, it was decided to make a 
construct from a 1. 3kb fragment flanked by Bam HI and Sph I sites, 
which contained only the region coding for the US4 gene (fig 3.22b). 
Although the orientation of the gene(s) in Homer 5 was not expected to 
affect the expression in the transformants, it was decided to clone 
both fragments into the Hind III site of the vector in both 
orientations.
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In order to make these constructs, both fragments were cut from 
the plasmid pRB 425 (Materials 6) and first cloned into the 
appropriate sites of the plasmid vector pIC 20H (fig 3.22a & b) 
(Materials 6). The pIC-K/S construct was confirmed by restriction 
digestion with Xho I which yielded the expected fragments of 0. 9kb and 
4. 6kb. The pIC-B/S construct was confirmed by restriction digestion 
with Bgl I to yield fragments of 1. Okb and 3. 4kb. Having obtained 
these clones, pIC-K/S and pIC-B/S were digested with Hind III and the 
relevant fragment in each case was isolated from a low melting point 
agarose gel, and cloned into the Hind III site of Homer 5 
(fig 3.23b & c). These constructs were confirmed and the orientation 
of their inserts determined by single restriction digests with EcdRI 
and Bam HI (fig 3.24). The expected sizes of the restriction 
fragments were as follows;
recombinants Bam HI digests Hind III digests £coRI digests
H5-Ka 1.9, 9.5 2.8, 8. 7
H5-Kb 1.7, 9.7 2. 8, 8. 7
H5-Ba 0.35, 9.6 1.3, 8. 7 0. 35, 0.54, 1.9, 6.8
H5-Bb 1.7, 8.3 1.3, 8. 7 0. 54, 1.7, 1.9, 5.5
Each of the four plasmids H5-Ka, H5_Kb, H5-Ba and H5-Bb 
(fig 3.23a & b), were transformed into 208F cells by calcium phosphate 
precipitation (Spandidos & Wilkie, 1984b). After 3 days, 300pg/ml 
geneticin was added to the medium to allow selection of transformed 
cells. After a further 3 days, two geneticin-resistant colonies were
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picked from each transformation reaction for further characterisation. 
The resulting cell lines were named as follows;
expression plasmid cell line
H5-Ka Ka-1 and Ka-2
H5-Kb Kb-1 and Kb-2
H5-Ba Ba-1 and Ba-2
H5-Bb Bb-1 and Bb-2
E. 2 Attempts to detect HSV-PK and characterisation of the phenotype of 
transformant cell lines.
The activity of HSV-PK can be detected in an assay using 
protamine as a substrate. However, since protamine is also a 
substrate for protein kinase C, it is necessary to separate the two 
kinases in order to detect the activity of the viral kinase. This can 
be achieved by subjecting the post-ribosomal supernatant to 
chromatography on DEAE-cellulose (Methods 8.2bi). Protein kinase C 
elutes at a KC1 concentration of approximately 0. 05M, whereas the 
viral kinase elutes at approximately 0. 2M KC1 (Katan et al., 1985). 
Extracts were prepared from five confluent roller bottles of the 
transformants Ka-2 and Kb-2, and the parent cell line, 208F 
(Methods 8.2a). Comparison of the protein kinase activity profiles 
from chromatography of each extract showed no appreciable differences 
(fig 3.25). Thus, if there was expression of the protein kinase it
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was not sufficient to be detected by this method.
The phenotype of the transformant cell lines was also 
investigated. Comparison of the appearance of the transformants with 
the parent cell line 208F (fig 3.26), suggested that these cell lines 
were not malignantly transformed.
Cell growth curves were performed for the cell lines 208F, Ka-2 
and Kb-2 (fig 3.27) (Methods 5.3). These showed that the density of 
the cells at confluence did not differ significantly between the 
parent cell line and Kb-2 but was slightly less for Ka-2. This may 
indicate that Ka-2 cells are less transformed than the parent cell 
lines.
After nine months in culture, growth curves were performed on the 
cell lines in the presence and absence of 300pg/ml geneticin 
(Methods 5.3) in order to determine if expression of geneticin 
resistance, which had been used to select the transformants, had been 
retained even though the cells had since been grown under conditions 
which did not require the expression of this gene. Comparison of the 
growth curves for Ka-2 and Kb-2 in the presence and absence of 
300pg/ml geneticin with those for 208F showed that, although the 
growth of Ka-2 and Kb-2 was slower in the presence of geneticin, the 
sensitivity to this antibiotic, was much less than that of the parent 
cell line which was completely inhibited at this concentration 
(fig 3.28). Thus Ka-2 and Kb-2 have maintained the expression of the 
geneticin resistance gene.
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The results of this work were inconclusive since over—expression 
of the viral kinase was not achieved. It has been found in other 
studies with stable transformants that there can be a large variation 
(eg. 50-fold) in the extent of expression of foreign genes for which 
there is no direct selection (Housey et al., 1988). Low levels of 
expression of the foreign gene may result from deletions occurring 
within the gene during the process of integration, but this variation 
may also be due to differences in the number of copies of the gene 
which are incorporated in the cellular genome, the location at which 
integration occurs, and the degree of methylation of the gene. Any of 
these factors may explain the lack of detectable viral protein kinase 
activity in the four clones selected for resistance to geneticin but 
which did not appear to express the viral protein kinase.
The chance of obtaining clones over-expressing the viral protein 
kinase could have been increased by analysing more clones. For 
practical reasons, this would have required a more efficient method 
for screening the clones. At the time of this work, detection of the 
viral protein kinase was dependent on making an extract from the 
cells,- subjecting this to chromatography on an analytical scale, and 
detecting the protein kinase activity in certain fractions from the 
column. This necessarily required the cells to be grown on a 
relatively large scale. However, as a result of other aspects of the 
work described in this thesis, there is now another approach which 
might allow screening to be carried out on fewer cells. Anti-serum S 
(raised against the HSV-1 protein kinase fusion-protein) might be 
suitable for use in immunoprecipitations or immunoblots to detect 
HSV-PK in extracts prepared from the transformants. Although
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immunoblots were performed on post-ribosomal supernatants, and various 
fractions from analytical DEAE-cellulose chromatography of extracts ’ 
(Methods 8.2bi) from the transformants Ka-2 and Kb-2, no positive 
signal was detected. Since immunoblots using this anti-serum were 
able to detect HSV-PK in post-ribosomal supernatants and the relevant 
fractions from analytical DEAE-cellulose chromatography of extracts 
from cells infected with HSV-1, it would suggest that this approach 
would allow the detection of HSV-PK, in cells in which it is 
expressed.
The extent of expression of a fragment of foreign DNA is partly 
determined by the strength of the promoter from which it is expressed 
and also possible enhancer elements. In the constructs used in this 
work, the US3 gene was to be expressed from its own promoter, enhanced 
by the SV40 enhancer. This enhancer can significantly increase the 
level of expression of a gene, as is indicated by the work of 
Spandidos and Wilkie (1984a). Transformants expressing oncogenic 
Ha-ras-1 from its own promoter alone were not morphologically 
transformed, whereas 25% of the colonies were morphologically 
transformed when this gene was expressed in Homer 5 in the presence of 
the SV40 enhancer. However, a further 4-fold enhancement was achieved 
by expressing the gene in Homer 6 in which the gene is flanked by both 
the SV40 enhancer and the Moloney murine sarcoma virus long terminal 
repeat. Such an approach might also increase the expression of the 
US3 gene. There is also the possibility that over-expression of the 
viral protein kinase may inhibit cell growth, in which case, 
expression of the gene from an inducible promoter might be more 
successful (eg. the mouse metallothionein promoter which can be
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induced by zinc; Spandidos & Wilkie, 1984b>.
Another approach to increase the yield of high-expression cell 
lines is to cotransfect with two marker genes and select for cells 
expressing both of them. Wirth et al. (1988) have shown that when 
cells were cotransfected with the genes conferring resistance to 
geneticin and puromycin along with the gene for interferon 8, and 
selected for resistance to both antibiotics, the resulting cells 
secreted 20 times as much interferon 3 as cells selected for 
resistance to geneticin alone. Clones expressing a large amount of 
the foreign protein did not necessarily have a high copy number of the 
transfected DNA, suggesting that other factors such as the site of 
integration and the extent of methylation are more important in 
determining the level of expression.
Thus, there are several approaches which could be used in the 
future to improve the chances of obtaining efficient expression of the 
US3 gene from transformed eukaryotic cells.
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Figure 3. 1 Schematic diagrams of the expression vector pUEX and the 
recombinants plfEX-P and pUEX-S for expression of protein kinase 
f usion-proteins.
a) pUEX contains three genes, lac z, amp* and the bacterial phage 
lambda gene, cl 857. The lac z gene is expressed from the lambda 
cro promoter, which is sensitive to repression by the lambda 
repressor, cl. cl 657 is a temperature sensitive mutant which is 
non-functional at 42°C. The DNA to be expressed, is inserted into 
the multiple cloning site located at the 3‘ end of the lac z gene. 
Expression of the fusion-protein in E. coll is induced by incubation 
at 42°C.
b) pUEX-P, the construct for expression of the PRV fusion-protein.
A 0. 8kb Pst I fragment from pPRVB 10 (Materials 6), which contains 
most of the coding region of the pk gene, was cloned into the Pst I 
site of pUEX-1.
c) pUEX-S, the construct for expression of the HSV-1 fusion-protein.
A 0. 8kb Sal I fragment from pRB 425 (Materials 6), which encodes most 
of the protein kinase catalytic domain of the US3 gene, was cloned 
into the Sal I site of pUEX-1.
- 106-
b pPRVB 10
Barn HI
i
- c
Bam 10
EcoRV Pst] BamHI Pst I
Pst! BannHl \ PstI' i
06kb
BamHI
pUEX-P
75kb
pRB42S
Hind Dl
Sail BamHI Sail
US3V
\  Sail
SstI
BamHI
pUEX-S
75kb
Figure 3.2 Construction of pUEX-P and pUEX-S: Identification of 
clones with the insert in the desired orientation by restriction 
digestion with Baa HI.
Restriction digestions were carried out (Methods 3.1) and subjected 
to electrophoresis on a 1% agarose gel (Methods 4.1a).
a) Construction of pUEX-P
1) Restriction digestion of clone having the desired orientation
2) Uncut DNA from clone having the correct orientation
3) Restriction digestion of pUEX-1
4) DNA size markers : 7. 2kb, 4. 5kb, 3. lkb, 0. 4kb
b) Construction of pUEX-S
1) Restriction digestion of clone having the undesired orientation
2) Restriction digestion of clone having the desired orientation
3) Restriction digestion of pUEX-1
4) DNA size markers : 7. 2kb, 4. 5kb, 3. lkb, 0. 4kb
Numbers to the right of figures indicate the sizes of DNA markers 
in kb. Numbers to the left of figures indicate the sizes of DNA 
fragments in kb.
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Figure 3. 3 Time course of expression of p-galactosldase and the 
HSV-1 fusion-protein in E.coli.
E, coll transformed with pUEX-1 (a & b) or pUEX-S (c & d)
(Methods 1.2) were grown for 5h at 30°C. Expression of 
(3-galactosidase (b> and the HSV-1 fusion-protein (d) was then induced 
by increasing the temperature of incubation to 42°C (Methods 10. 1).
In a and c, the cells were maintained at 30°C. At Oh, lh, 2h, 3h and 
4h after induction, 1ml aliquots were collected and used to prepare 
total cell extracts. The cells were sedimented by centrifugation and 
the precipitates were dissolved in sample loading buffer 
(Methods 4. 2) These were subjected to polyacrylamide gel 
electrophoresis and the gel was stained for protein with 
Coomassie Blue (Methods 4.2a).
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46kDa (Materials 2).
F indicates the induced fusion-protein.
{3 indicates induced {3-galactosidase.
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Figure 3.4- Extraction of fusion-proteins from E. coll.
Extracts were prepared from E. coll either by resuspending the 
sedimented cells in sample loading buffer (Methods 4.2) to give 
a total cell extract, or lysing the cells with lysosyme and NP-40 
(Methods 10.2) and sedimenting the insoluble material by 
centrifugation. This supernatant was collected and the precipitate 
was dissolved in sample loading buffer. All three extracts were 
analysed by polyacrylamide gel electrophoresis (Methods 4.2a). 
a 1) Total cell extract from cells expressing p-galactosidase
2) Extract containing soluble material from cells expressing 
p-galactosidase
3) Extract containing precipitated material from cells expressing 
3-galactosidase
4) Total cell extract from uninduced cells
5) Extract containing soluble material from uninduced cells
6) Extract containing precipitated material from uninduced cells
7) Total cell extract from cells expressing the PRV 
f usion-protein
8) Extract containing soluble material from cells expressing the 
PRV fusion-protein
9) Extract containing precipitated material from cells expressing 
the PRV fusion-protein
b 1) Total cell extract from uninduced cells
2) Extract containing soluble material from uninduced cells
3) Extract containing precipitated material from uninduced cells
4) Total cell extract from cells expressing the HSV-1 
f usion-protein
5) Extract containing soluble material from cells expressing the 
HSV-1 fusion-protein
6) Extract containing precipitated material from cells expressing 
the HSV-1 fusion-protein
M indicates the molecular masses of the ’Rainbow' protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46k0a, 30kDa. (Materials 2)
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Figure 3.5 Partial purification of the PRV fusion-protein by
chromatography on Sephacryl S300.
Extracts from cells expressing the fusion-protein (prepared according 
to Methods 10.2) were subjected to chromatography on Sephacryl S300 
(Methods 10.3) and 40 fractions of 1ml were collected. The position 
of elution of protein from the column was determined by measuring the 
A2eo* The protein composition of the fractions was analysed by 
subjecting 30pl aliquots from fractions to polyacrylamide gel 
electrophoresis and staining the gel with Coomassie Blue 
(Methods 4.2a).
F indicates the position of the fusion-protein.
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Figure 3.6 Partial purification of the HSV-1 fusion-protein by
chromatography on Sephacryl S300.
Extracts from cells expressing the fusion-protein (prepared according 
to Methods 10.2> were subjected to chromatography on Sephacryl S300 
(Methods 10.3) and 40 fractions of 1ml were collected. The position 
of elution of protein from the column was determined by measuring the 
A2eo. The protein composition of the fractions was analysed by 
subjecting 30pl aliquots from fractions to polyacrylamide gel 
electrophoresis and staining the gel with Coomassie Blue 
(Methods 4.2a).
F indicates the position of the fusion-protein.
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46kDa (Materials 2)
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Figure 3. 7
a) Polyacrylamide gel electrophoresis of partially purified 
f usion-proteins.
The first fraction (from the Sephacryl S300 column; Methods 10.3) 
which contained the fusion-protein, was pooled from four columns.
This material was used to inject into rabbits to raise anti-sera 
(Methods 10.4). The second fractions from the columns were also 
pooled. This material was used in immunoblots to test the anti-sera.
1) PRV fusion-protein: pooled second fraction
2) PRV fusion-protein: pooled first fraction
3) HSV-1 fusion-protein: pooled second fraction
4) HSV-1 fusion-protein: pooled first fraction
5) {3-galactosidase: pooled first fraction
6) p-galactosidase: pooled second fraction
b) Characterisation of anti-sera and pre-lmmune sera with respect to 
the fusion-proteins.
Anti-sera and pre-immune sera were prepared according to 
Methods 11.2. The following dilutions were used for the anti-sera 
and pre-immune sera: anti-serum P was diluted 1:2000, anti-serum S 
was diluted 1:400, pre-immune serum corresponding to anti-serum P was 
diluted 1:400 and the pre-immune serum corresponding to anti-serum S 
was diluted 1: 100. These were used in an immunoblot (Methods 12) 
against fractions from the S300 columns containing the partially 
purified fusion proteins (fig 3.7a lane 2 & 3)
1) anti-serum P against the PRV fusion-protein
2) anti-serum P against the HSV-1 fusion-protein
3) anti-serum S against the PRV fusion-protein
4) anti-serum S against the HSV-1 fusion-protein
5) pre-immune serum from rabbit S against the PRV fusion-protein
6) pre-immune serum from rabbit S against the HSV-1
f usion-protein
7) pre-immune serum from rabbit P against the PRV fusion-protein
8) pre-immune serum from rabbit P against the HSV-l
fusion-protein
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 200kDa, 96kDa, 69kDa, 46kDa (Materials 2).
The lines between lanes 2 A 3, 4 & 5, 6 & 7, and between the 
molecular weight markers, 46 and 69 are cuts in the nitrocellulose 
filter (Methods 12).
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Figure 3.8 Activity of anti-serum P towards extracts from uninfected
cells and cells Infected with PRV and HSV-1.
Anti-serum P (prepared according to Methods 11.2) was used at a 
dilution of 1:400 in an immunoblot (Methods 12) against the following 
protein extracts: 
a 1-3) stages from purification of PRV-PK (Methods 8.2):
1) TSK phenyl-5PW
2) post-ribosomal supernatant
3) DEAE-cellulose
4) post-ribosomal supernatant from uninfected cells 
(Methods 8. 2a)
Numbers to the right indicate the molecular masses of the bands in 
kDa.
b 1) post-ribosomal supernatant from uninfected cells 
(Methods 8. 2a)
2) material from DEAE-cellulose stage of the purification of 
HSV-1 PK (as for PRV-PK, Methods 8.2b)
3) material from TSK phenyl-5PW stage of the purification of 
PRV-PK (Methods 8.2c)
Lane 3 also contains ' Rainbow' molecular weight markers 
(Materials 2). The position of these were marked with a biro before 
incubation with the first anti-serum and had molecular masses of 
69kDa, 46kDa and 30kDa as indicated (numbers to the right).
Numbers to the left indicate the molecular masses of the bands in 
kDa.
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Figure 3.9 Activity of anti-serum S towards extracts from uninfected
cells and cells infected with PRV or HSV-1.
Anti-serum S (prepared according to Methods 11.2) was used at a 
dilution of 1: 100 in an immunoblot (Methods 12) against the following 
protein extracts:
1) partially purified HSV-1 fusion-protein (fig 3.7a lane 3)
2) material from DEAE-cellulose stage of HSV-1 protein kinase 
purification (as for PRV-PK, Methods 8.2b)
3) post-ribosomal supernatant from uninfected cells 
(Methods 8. 2a)
4) post-ribosomal supernatant from cells infected with PRV 
(Methods 8. 2a)
Numbers to the left indicate the molecular masses of the bands 
in kDa.
M indicates the molecular masses of the 'Rainbow' protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46kDa, 30kDa (Materials 2).
-114-
1 2 3 A M
1 4 0 -
6 9 -  
68 ~
■96
69
3A
- A 6
- 3 0
Figure 3. 10 Purification of PRV-PK.
Fractions from the stages of the purification were analysed by 
polyacrylamide gel electrophoresis (Methods 4. 2a> and stained with 
Coomassie Blue (1-5) or by silver staining (lane 6a & 6b;
Methods 4. 2b).
1) post-ribosomal supernatant (Methods 8.2a)
2) pooled fractions from DEAE-cellulose column after concentration 
using Aquacide II (Methods 8. 2bii)
3) fraction 46 from TSK phenyl-5PW column (fig 3. 12)
4) fraction 70 from TSK phenyl-5PW column (fig 3. 12)
5) fraction 60 from threonine-Sepharose column (fig 3. 13)
6a) fraction 30 from protamine-agarose column (fig 3. 14)
6b) fraction 37 from protamine-agarose column (fig 3. 14)
M indicates the molecular masses of the 'Rainbow' protein molecular 
weight markers in kDa : 200kDa, 96kDa, 69kDa, 46kDa, 30kDa 
(Materials 2).
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Figure 3.11 Purification of PRV-PK: DEAE-cellulose column.
a) Protein was eluted from this column using a salt gradient of 
0 - 0. 4M KC1 (Methods 8.2bii). 60 fractions of 7ml were collected 
and assayed for protein kinase activity (Methods 8. 1).
— a— indicates protein kinase activity (cpm xl0"®>
 indicates KC1 concentration (M).
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Figure 3.11 Purification of PRV-PK: DEAE-cellulose column.
b) Imraunoblots (Methods 12) were performed on the material from 
various fractions after precipitation of the protein with acetone 
(Methods 4.2c). Anti-serum P (prepared according to Methods 11.2) 
was used at a dilution of 1:400.
M indicates the molecular masses of the 'Rainbow' protein molecular 
weight markers in kDa : 69kDa, 46kDa, 30kDa (Materials 2).
S indicates the lane which contained material from the post-ribosomal 
supernatant from cells infected with PRV (Methods 8.2a)
Numbers to the left indicate the molecular masses of the bands 
in kDa.
The line within lane M corresponds to where the nitrocellulose filter 
was cut (Methods 12).
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Figure 3. 12 Purification of PRV-PK: TSK phenyl-5PW column.
Fractions corresponding to the peak of PRV-PK from six DEAE-cellulose 
columns were pooled and subjected to chromatography on a 
TSK phenyl-5PW column. Protein was eluted from this column using a 
salt gradient of 1.0 - 0M ammonium sulphate (Methods 8.2c). 80
fractions of 1ml were collected and assayed for protein kinase 
activity (Methods 8. 1). Immunoblots (Methods 12) were performed on 
the fractions shown to contain protein kinase activity. 50p.l 
aliquots of each fraction were used. Anti-serum P (prepared 
according to Methods 11.2) was used at a dilution of 1:400
M indicates the molecular masses of the 'Rainbow' protein molecular 
weight markers in kDa : 69kDa, 46kDa, 30kDa (Materials 2).
Number to the right indicates the molecular mass of the band in kDa. 
The line between fractions 46 & 48 is where the nitrocellulose filter 
was cut (Methods 12).
— Q— indicates protein kinase activity (cpm xlO”*)
 indicates ammonium sulphate concentration (M).
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Figure 3. 13 Purification of PRV-PK: Threonine-Sepharose column.
Fractions 37-44, 49-54 and 62-72 from the TSK phenyl-5PW column 
(fig 3. 12) were pooled and subjected to chromatography on a 
threonine-Sepharose column. Protein was eluted from this column 
using a salt gradient of 0 - 1. OM KC1 (Methods 8. 2d) . 70 fractions
of 2ml were collected and assayed for protein kinase activity 
(Methods 8. 1) and the protein concentration determined by Bradford 
assays. Immunoblots (Methods 12) were performed on the fractions 
corresponding to the peak of protein kinase activity using 50pl 
aliquots from each fraction. Anti-serum P (prepared according to 
Methods 11.2) was used at a dilution of 1:400.
M indicates the molecular masses of the ' Rainbow1 protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46kDa, 30kDa (Materials 2).
The line within fraction 59 is where the nitrocellulose filter was 
cut (Methods 12).
— +— indicates protein kinase activity (cpra xlO”*)
— P— indicates protein concentration (mg/ml)
 indicates KC1 concentration (M).
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Figure 3. 14 Purification of PRV-PK: Protamine-agarose column.
Fractions 55-62 from the threonine-Sepharose column (fig 3.13) were 
pooled and subjected to chromatography on a protamine-agarose column. 
Protein was eluted from this column using a salt step gradient of 
0 - 1. OM KC1 (Methods 8.2e). 60 fractions of 1ml were collected and
assayed for protein kinase activity (Methods 8.1) and the protein 
concentration determined by Bradford assays. Immunoblots (Methods 
12) were performed on the fractions in which protein kinase activity 
was detected. 50jil of each fraction was used. Anti-serum P 
(prepared according to Methods 11.2) was used at a dilution of 1:400. 
A 15% polyacrylamide gel was used.
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 200kDa, 96kDa, 69kDa, 46kDa, 30kDa, 21kDa 
(Materials 2).
The line between fractions 36 & 38 is where the nitrocellulose filter 
was cut (Methods 12).
— □— indicates protein kinase activity (cpm xlO**3)
— — indicates protein concentration (pg/ml)
 indicates KC1 concentration (M).
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Figure 3. 15 Characterleation of affinity-purified antibodies.
a) Immunoblot using antibodies affinity-purified against PRV-PK. 
Antibodies were eluted from PRV-PK (material from TSK phenyl-5PW 
column stage of purification ie. Methods 8.2c) bound to 
nitrocellulose filters (Methods 11.3) and used in an immunoblot 
(Methods 12) at a dilution of 1:5 against extracts from infected and 
uninfected cells:
1) material from DEAE-cellulose stage of purification of HSV-PK 
(as for PRV-PK, Methods 8.2bii)
2) post-ribosomal supernatant from uninfected cells (Methods 8.2a)
3) material from DEAE-cellulose stage of purification of PRV-PK 
(Methods 8.2bii)
4) post-ribosomal supernatant from cells infected with PRV-PK 
(Methods 8. 2a)
Lane 4 also contained ' Rainbow' protein molecular weight markers, the 
positions of which were marked in biro before incubation with the 
first anti-serum (Methods 12). These correspond to the lines at 
69 and 46.
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 69kDa, 46kDa (Materials 2).
Numbers to the left indicate the molecular masses of the bands 
in kDa.
The line above the 69 marker is where the nitrocellulose filter was 
cut (Methods 12).
b) Immunoblot using antibodies affinity-purified against the 34kDa 
cellular protein. Antibodies were eluted from the 34kDa cellular 
protein (Methods 11.3) and used in an immunoblot at a dilution of 1:4 
(Methods 12).
1) Immunoblot of antibodies affinity-purified against the 34kDa 
cellular protein against material from the TSK phenyl-5PW stage 
of the purification of PRV-PK.
2) Immunoblot of anti-serum P (prepared according to Methods 11.2) 
against material which eluted from the DEAE-cellulose column at
0. 1M KC1 during the purification of PRV-PK (fig 3. 11). This shows 
the 34kDa band from which antibodies were eluted.
Lane 2 also contained 'Rainbow' protein molecular weight markers, the 
positions of which were marked in biro before incubation with the 
first anti-serum (Methods 12). These correspond to the lines at 69 
46 and 30.
The line in lane 1 below the 38kDa band is where the nitrocellulose 
filter was cut (Methods 12).
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 69kDa, 46kDa, 30kDa (Materials 2).
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Figure 3. 16
a) Protein and immunochemical analysis of PRV virions and 
nucleocapsids.
Virions and nucleocapsids were prepared according to Methods 7. 1. 
lOpl of virions and nucleocapsids were subjected to polyacrylamide 
gel electrophoresis and stained for protein with Coomassie Blue 
(Methods 4. 2a)
lane la : virions prepared from the growth medium of infected 
cells
lane lb : virions prepared from the cytosol of infected 
cells
lane 2 : nucleocapsids prepared from the nuclei of infected
cells
Anti-serum P (prepared according to Methods 11.2) was used in an 
immunoblot (Methods 12) at a dilution of 1:400 against virions 
(from 3 roller bottles of infected cells) and nucleocapsids 
(prepared according to Methods 7. 1), and an extract from infected 
cells (the concentrated material from the DEAE-cellulose column 
equivalent to that produced from 0.03 roller bottles of infected 
cells : Methods 8.2bii)
lane 3 : DEAE-cellulose material from infected cells 
lane 4 : PRV nucleocapsids
lane 5 : PRV virions prepared from the growth medium of infected 
cells
b) Immunochemical analysis of extracts of PRV virions after 
treatment with NP-40.
1 OpLl of PRV virions (prepared according to Methods 7. 1) were treated 
with 1% NP-40 or 10% NP-40, 0. 6M NaCl (Methods 7.2). Anti-serum P 
(prepared according to Methods 11.2) was used in an immunoblot 
(Methods 12) against the solubilised material and the precipitate 
resulting from both these extraction procedures at a dilution of 
1: 400
lane 1 : precipitate after extraction with 1% NP-40
lane 2 : soluble material from extraction with 1% NP-40
lane 3 : precipitate after extraction with 10% NP-40, 0,6M NaCl
lane 4 : soluble material from extraction with 10% NP-40,
0. 6M NaCl
lane 5 : DEAE-cellulose material from infected cells
(Methods 8.2bii)
The line within lane 3 is where the nitrocellulose filter was cut 
(Methods 12).
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 200kDa, 96kDa, 69kDa, 46kDa, 30kDa 
(Materials 2).
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Figure 3. 17 Immunochemical analysis of HSV-1 virions using 
anti-serum S.
Mature HSV-1 virions were prepared from the medium from infected 
cells Cas for PRV, Methods 7.1). Nucleocapsids were prepared from 
the nuclei of infected cells (as for PRV, Methods 7. 1). Anti-serum S 
(prepared according to Methods 11.2) was used at a dilution of 1: 100 
in immunoblots against these preparations (Methods 12).
1) partially purified HSV-1 fusion-protein (fig 3.7 lane 3)
2) material from the DEAE-cellulose stage of the purification of 
HSV-1 PK (as for PRV, Methods 8.2bii)
3) HSV-1 nucleocapsids
4) HSV-1 mature virions
M indicates the molecular masses of the 'Rainbow' protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46kDa, 30kDa (Materials 2). 
Numbers to the left indicate the molecular masses of the bands 
in kDa.
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Figure 3. 18
a) The proteins phosphorylated in extracts prepared from cells 
Incubated with C22P]orthophosphate during infection with PRV or 
during mock-infection.
Two 25cm2 flasks were infected and 0. 3mCi/flask [®2P3orthophosphate 
was added 12h post-infection. (Methods 9.2). The cells were 
harvested 3h later (Methods 9. 2a) and an extract produced (200pl). 
Similarly, an extract was made from two 25cm2 flasks of mock-infected 
cells after labelling for 3h. These were subjected to polyacrylamide 
gel electrophoresis (Methods 4. 2a) and an autoradiograph produced 
(Methods 9.3).
lane 1: Ijil purified virions incubated with y[*2P]ATP
(ie. phosphorylation by endogenous protein kinases in 
vitro. Methods 9. la) 
lane 2: 10y.l of extract from infected cells
lane 3: 30^1 of extract from infected cells
lane 4: 10p.l of extract from mock-infected cells
lane 5: 30^1 of extract from mock-infected cells
b A c) The phosphorylation of the viral structural proteins of PRV 
in viva
Two 25cm2 flasks were infected and lmCi/flask C32P1orthophosphate 
added 3h post-infection (Methods 9.2). The virions were harvested 
20h after infection (Methods 9.2b) and an extract produced (200pl).
An extract was similarly prepared from two 25cm2 flasks of cells 
mock-infected and incubated with lmCi/flask t32P]orthophosphate for 
17h. These were subjected to polyacrylamide gel electrophoresis 
(Methods 4.2a) and an autoradiograph produced (Methods 9.3).
b) lane 1: 30p.l virion extract 
lane 2: 20^1 virion extract
lane 3: 1 p.1 purified virions incubated with yC32P3ATP
(ie. phosphorylation by endogenous protein kinases in 
vitro. Methods 9. la)
c) lane 1: 30|il virion extract
lane 2: 30pl extract prepared from mock-infected cells
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 200kDa, 96kDa, 69kDa, 46kDa, 30kDa 
(Materials 2).
Numbers to the right of a and c, and to the left of b indicate the 
molecular masses of the bands in kDa.
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Figure 3. 19 The phosphorylation of structural proteins of heat- 
inactivated PRV virions by PRV-PK, cAMP-dependent protein kinase and 
casein kinase II.
1^ 1 of virions (prepared according to Methods 7. 1) were 
heat-inactivated and incubated with YC3aP]ATP (Methods 9.1b) in the 
presence or absence of exogenously added protein kinases and 
subjected to electrophoresis on a 15% polyacrylamide gel 
(Methods 4.2a). The protein kinases were also incubated with 
Yt3aP3ATP under the same conditions, but in the absence of the 
heat-inactivated virions, and subjected to electrophoresis.
An autoradiograph was produced (Methods 9. 3).
lane 1: crude preparation of casein kinase II incubated with
Y[3aP3ATP without heat-inactivated virions
lane 2: crude preparation of casein kinase II incubated with
YC3aP3ATP and heat-inactivated virions 
lane 3: pure cAMP-dependent protein kinase incubated with 
Yt®aP]ATP without heat-inactivated virions 
lane 4: pure cAMP-dependent protein kinase incubated with 
YC3aP]ATP and heat-inactivated virions 
lane 5: highly purified PRV-PK (from threonine-Sepharose column) 
incubated with Y^*aP^ATP without heat-inactivated 
virions
lane 6: highly purified PRV-PK (from threonine-Sepharose column) 
incubated with Y^3aP3ATP and heat-inactivated virions 
lane 7: heat-inactivated virions incubated with Yt3aPJATP 
lane 8a A b: virions incubated with y[9StP]ATP (Methods 9. la)
M indicates the molecular masses of the ' Rainbow' protein molecular 
weight markers in kDa : 96kDa, 69kDa, 46kDa, 30kDa (Materials 2). 
Numbers to the right indicate the molecular masses of the bands in 
kDa.
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Figure 3. 20 The phosphorylation of nucleocapslds by endogenous and 
exogenous protein kinases i n  v i t r o .
lane 1 : phosphorylation of PRV virions by endogenous protein 
kinases (Methods 9. la) 
lanes 2 & 5 : 5(j l1 of nucleocapslds (prepared according to 
Methods 7.1) were incubated with yC33P3ATP in the 
presence of 0. 5M (2) or 50mM (5) KC1 (Methods 9. la) 
lanes 3 & 4 : 5j jl1 of nucleocapslds (prepared according to
Methods 7. 1) were heat-inactivated and incubated with 
YC3aPlATP in the presence (3) or absence (4) of PRV-PK 
(highly purified PRV-PK from threonine-Sepharose column) 
(Methods 9. lb).
After the incubations, the reaction mixture was subjected to 
polyacrylamide gel electrophoresis (Methods 4.2a) and an 
autoradiograph produced (Methods 9.3).
Numbers to the left show molecular masses (in kDa) of proteins 
phosphorylated by endogenous protein kinases as calculated from 
fig 3. 19. Numbers to the right indicate the molecular masses deduced 
for the phosphoproteins in the nucleocapslds.
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Figure 3.21 The effect of heparin, polyarginine and 0. 5M KC1 on the 
phosphorylation of PRV virions by the endogenous protein kinase 
activity in vitro.
Ijj.1 of virions (prepared according to Methods 7. 1) were incubated 
with yC33P]ATP (Methods 9. la) in the presence or absence of 0. 5M KC1, 
ljig/ml heparin, or 0. 5mg/ml polyarginine and subjected to 
polyacrylamide gel electrophoresis (Methods 4.2a) on a 15% gel (a) or 
10% gel (b). Autoradiographs were produced (Methods 9.3)
a) lane 1 
lane 2 
lane 3
b) lane 1 
lane 2
lane 3
endogenous phosphorylation in absence of inhibitors 
endogenous phosphorylation in presence of 0. 5M KC1 
endogenous phosphorylation in presence of lpg/ml heparin
endogenous phosphorylation in absence of inhibitors 
endogenous phosphorylation in presence of 0. 5mg/ml 
polyarginine
endogenous phosphorylation in presence of 0. 5M KC1
M indicates the molecular masses of the 'Rainbow' protein molecular 
weight markers in kDa : 200kDa, 96kDa, 69kDa, 46kDa, 30kDa, 21kDa 
(Materials 2).
Numbers to the right of a and left of b indicate the molecular masses 
of the bands in kDa.
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Figure 3.22 Schematic diagrams of pIC 2QH and the recombinants 
pIC-K/S and pIC-B/S.
a) pIC 20H is a vector which allows a restriction fragment which has 
been produced by restriction digestion with one or two of a number of 
restriction endonucleases, including Kpn I, Bam HI and Sph 1, to be 
converted to a Hind III fragment. The vector has a sequence which 
contains unique sites for a number of restriction endonucleases.
These sites are flanked by two sites for Hind III. This sequence is 
located within lac z, thus allowing recombinants to be identified by 
colour selection using IPTG and X-gal.
b)
The construction of pIC-K/S. The 2. 8kb Kpn I / Sph I fragment from 
pRB 425 (Materials 6) was inserted into the multiple cloning site of 
pIC 20H. This fragment includes the promoter and the information for 
the complete mRNA transcript of US3 and US4.
The construction of pIC-B/S. The 1. 3kb Bam HI /Sph I fragment from 
pRB 425 was inserted into the multiple cloning site of pIC 20H. This 
fragment contains the coding region of (JS4.
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Figure 3.23 Schematic diagrams of Homer 5 and the recombinants 
H5-Ka, H5-Kb, H5-Ba and H5-Bb.
a) Homer 5 contains two genes, ampR and aph which confer resistance 
to ampicillin and geneticin respectively. It also contains the SV40 
enhancer located near the unique Hind III site, which is the cloning 
site for the gene to be expressed. Expression of aph, which is a 
bacterial gene, is made possible by the promoter and termination 
signal sequences from the thymidine kinase gene (TK) of HSV-1 which 
flank the gene.
b) The construction of H5-Ka and H5-Kb. The 2. 8kb Hind III fragment
from pIC-K/S was cloned into the Hind III site of Homer 5. The
orientation of the insert was determined by restriction digestion 
with Bam HI.
c) The construction of H5-Ba and H5-Bb. The 1. 3kb Hind III fragment
from pIC-B/S was cloned into the Hind III site of Homer 5. The
orientation of the insert was determined by restriction digestion 
with Bam HI and EcoRI.
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Figure 3. 24 Construction of H5-Ka, H5-Kb, H5-Ba, and H5-Bb:
Confirnation of identity of clones and determination of orientation 
by restriction digestion.
Restriction digestions were carried out according to Methods 3. 1 and 
subjected to electrophoresis on a 1% agarose gel (Methods 4. la)
lane M DNA size markers: 5. 9kb, 4. 3kb, 3. 3kb & 1. 7kb
lane 1 restriction digestion of H5-Kb with Bam HI
lane 2 restriction digestion of H5-Kb with Hind III
lane 3 restriction digestion of H5-Ka with Bam HI
lane 4 restriction digestion of H5-Ka with Hind III
lane 5 restriction digestion of H5-Bb with FcoRI
lane 6 restriction digestion of H5-Bb with Bam HI
lane 7 restriction digestion of H5-Bb with Hind III
lane 8 restriction digestion of H5-Ba with EcdRI
lane 9 restriction digestion of H5-Ba with Bam HI
lane 10 restriction digestion of H5-Ba with Hind III
M indicates the sizes of the DNA size markers in kb.
Numbers to the right indicate the sizes of the bands in kb.
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Figure 3. 25 Analysis of protein kinase activity present In the cell 
lines 208F, Ka-2 and Kb-2.
Post-ribosomal supernatants (Methods 8.2a) prepared from five roller 
bottles of each cell line were subjected to chromatography on 
DEAE-cellulose (Methods 8.2bi>. Protein was eluted from the column 
using a salt gradient of 0 - 0. 4M KC1. Protein kinase activity was 
detected by assaying with protamine as the substrate (Methods 8. 1).
— Q-—  indicates protein kinase activity (cpm xlO”3)
 indicates KC1 concentration (M)
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Figure 3. 26 Light microscopic appearance of the cell line used for 
transformation with Homer constructs and resulting genetlcin 
resistant clones.
The cell line 208F was transformed with the constructs H5-Ka and 
H5-Kb by calcium phosphate precipitation. Transformants (Ka and Kb) 
were selected for by culturing in the presence of 300pg/ral geneticin.
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Figure 3. 27 Cell growth curves showing the rates of growth and 
saturation density of the cell lines 208F, Ka-2 and Kb-2.
Cells were grown in 60mm dishes (Methods 5.3), harvested by 
trypsinisation and counted using a Coulter counter. (The errors in 
the values for each point on the graph were less than 8%. )
— □—  indicates the cell line Kb-2
■ ■■+ — indicates the cell line 208F
— ■—  indicates the cell line Ka-2
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Figure 3. 28 Cell growth curves showing the rates of growth of the 
cell lines 208F, Ka-2 and Kb-2 in the presence and absence of 
300pg/nl geneticin.
Cells were grown in 60mm dishes (Methods 5. 3), harvested by 
trypsinisation and counted using a haemocytoraeter. (The errors in 
the values for each point on the graph were less than 8%. )
a) 208F
b) Ka-2
c) Kb-2
— □—  indicates cells grown in the presence of 300pg/ml geneticin 
— 0—  indicates cells grown in the absence of geneticin
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Chapter 4 
DISCUSSION
A. The relationship between the 38kDa protein kinase (PRV-PK) and the 
PRV pk gene.
The main aim of the work described in this thesis was to 
determine whether the 38kDa protein kinase (PRV-PK) purified from 
cells infected with PRV was the product of the pk gene of PRV, 
homologous to the US3 gene of HSV-1. The anti-serum raised against a 
fusion-protein of part of the gene showed immuno-reactivity against 
PRV-PK during its purification, including homogeneous material from 
the final stage, when transferred to nitrocellulose (fig 3.14). From 
this it can be concluded that PRV-PK is encoded by the pk gene of PRV 
and hence is of viral origin.
Previous work on HSV-1 (Frame et al., 1987) also used an 
immunochemical approach to determine the relationship between the US3 
gene and the protein kinase induced in cells infected with HSV-1.
This enzyme was purified 100-fold, and the final stage of its 
purification yielded material containing two species, of 65kDa and 
68kDa, of which only the 68kDa protein was phosphorylated when 
incubated with y£32P1ATP. Anti-serum against a synthetic 
oligopeptide corresponding to the carboxy-terminal eight amino acids 
of the US3 protein was found to react with the protein of 68kDa in 
immunoblots of fractions from the final two stages of the 
purification of HSV-PK. This showed that the 68kDa protein was the
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product of the US3 gene and suggested that it contained the HSV-PK 
activity which underwent autophosphorylation. The possibility 
remained, however, that the 65kDa protein contained the HSV-PK 
activity and that the viral 68kDa protein was a substrate for it.
In contrast, in this study, the purity of PRV-PK eliminates any 
possibility that the anti-serum is reacting with a protein other than 
the protein kinase.
The demonstration that PRV-PK is the product of the pk gene of 
PRV is of added importance in the light of recent papers by 
Smith & Smith (1989) and Chee et al. (1989) concerning another 
putative protein kinase gene in several different herpes viruses, 
namely HSV-1, VZV, EBV and HCMV. This gene, which corresponds to 
UL13 in HSV-1, was identified using the sequence motifs diagnostic of 
the catalytic domain of protein kinases (Introduction B.2). It is 
much more highly divergent from known cellular protein kinases than 
are the US3 gene and its homologues, but the presence of these motifs 
is quite suggestive that it could encode a protein kinase. The 
conservation of this gene among herpesviruses suggests that the 
genome of PRV may also contain a similar gene. However, this work 
identifies PRV-PK as being the product of the protein kinase gene 
which is related to that of the HSV-1 US3 gene rather than to that 
related to the UL13 gene.
One minor point that deserves comment is the fact that the 
behaviour of PRV-PK during purification differed in certain respects 
from that reported by Purves et al. (1987a). The final 
protamine-agarose column was found to yield two peaks of activity 
(fig 3. 14). The major peak eluted at the position in the salt
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gradient previously observed (Purves e< al., 1987a), but another peak 
eluted at a slightly lower ionic strength. Analysis of fractions 
containing protein kinase activity by polyacrylamide gel 
electrophoresis and visualising with silver stain showed that a 
single species of 38kDa was present in fractions from both peaks of 
activity (fig 3. 10 lane 6a & 6b). Multiple peaks were also observed 
in the material eluted from the TSK phenyl-5PW column (fig 3. 12), but
the first of these may have been protein kinase M, a proteolytic
product of protein kinase C which elutes at a higher salt
concentration than the latter on DEAE-cellulose and may not have been
completely resolved from PRV-PK on that column. Although the 
coelution of an inhibitor with PRV-PK in some fractions may account 
for some of the apparent peaks, they may also result from the 
presence of multiple forms of PRV-PK, differing in their 
chromatographic properties. This may also account for the two peaks 
observed in the material eluted from the protamine-agarose column.
The fact that the only protein detected in both peaks from the 
protamine-agarose column had a molecular weight of 38kDa makes it 
unlikely that the differences result from proteolysis. 
Autophosphorylation, which the enzyme is known to undergo 
(Purves et al., 1987a), is another possible explanation for the 
phenomenon, but as this question was peripheral to the main aim of 
the work, it was not further investigated.
Although the anti-serum reacted with PRV-PK through all stages of 
purification of the enzyme, it also showed one major cross-reaction 
with a cellular protein of 34kDa. This protein was present in 
post-ribosomal supernatants from infected and uninfected cells
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(fig 3.8), but was resolved from PRV-PK by chromatography on 
DEAE-cellulose (fig 3.11). Affinity-purification of the anti-serum, 
by binding to PRV-PK immobilised on a nitrocellulose filter followed 
by elution, gave anti-serum which still cross-reacted with this 34kDa 
protein, indicating that the latter must be antigenically related to 
PRV-PK (fig 3. 15a). Consistent with this result was the observation 
that anti-serum eluted from the 34kDa protein immobilised on 
nitrocellulose, cross-reacted with PRV-PK (fig 3.15b).
One possible explanation for this cross-reaction is that the 34kDa 
protein is a cellular homologue of the viral protein kinase. Since 
the 34kDa protein was not fully resolved from protein kinase C on 
DEAE-cellulose (fig 3. 11a), it was not possible to determine if this 
protein did show protein kinase activity. However it seems unlikely 
that a cellular homologue of PRV-PK would be sufficiently homologous 
for immuno-reaction, since the anti-serum to PRV-PK did not cross- 
react with the homologous protein kinase of HSV-1 
(fig 3.8b). Nor did anti-serum aganist HSV-PK cross-react with 
PRV-PK (fig 3.9). It seems more likely that the 34kDa protein is not 
a protein kinase but fortuitously has common epitopes.
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B. Occurence and implications of the presence of PRV-PK within the 
virions.
It was intended to use the anti-serum which recognised PRV-PK for 
immunofloresence studies to determine the location of this enzyme 
within infected cells. This might have shed some light on the 
physiological substrate of the viral protein kinase, and, hence, its 
function. However the fact that the anti-serum cross-reacted with a 
cellular protein, even after affinity-purification, meant that the 
anti-serum was unsuitable for such studies. Nevertheless, it was 
possible to use the anti-serum in immunoblotting to investigate a 
different aspect of the distribution of the viral protein kinase, 
namely its occurence within the virion.
The anti-serum was found to react with a single protein of 38kDa 
in purified PRV virions (fig 3. 16a). This indicated that PRV-PK is 
present within the virions. This result is unlikely to arise from 
contamination of the purified virions with proteins present in the 
infected cells for several reasons. Firstly, the virions were 
derived from the medium of infected cells rather than from the 
cytosol of infected cells, which reduces such contamination.
Secondly, the 34kDa cellular protein present in cellular extracts was 
not detected in the immunoblot. This result is not inconsistent with 
previous studies (Stevely et al. , 1985) in which the protein kinase
activities of PRV virions were investigated. A protein kinase 
activity was observed that could be PRV-PK on the basis of its 
preference for protamine as a substrate and its chromatographic
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properties on DEAE-cellulose. However, further characterisation of 
the enzyme was not carried out and thus its identity must still be 
considered ambiguous.
What is the significance of the location of the protein kinase in 
the virion? Although PRV-PK is present within PRV virions, it can 
be estimated from the immunoblot (fig 3.16a> that there is at least a 
10, times as much PRV-PK in the cytoplasm of infected cells as in the 
virions, even assuming that the yield of virions in the preparation 
was only 10%. Stevely et al. (1985) identified at least four protein 
kinase activities within PRV virions. The properties of the two 
activities which showed a preference for casein as a substrate 
suggested that they corresponded to the cellular protein kinases, 
casein kinase I and II. Of the two activities showing a preference 
for protamine, one was suggested to be protein kinase C, while the 
other enzyme could have been PRV-PK. Assuming this identification to 
be correct, the amount of PRV-PK present within the virion is 
approximately the same as that of these cellular protein kinases 
which are assumed to become fortuitously incorporated into the virion 
during the process of assembly. The fact that there appears to be no 
specific accumulation of PRV-PK as compared to the cellular protein 
kinases in PRV virions, along with the much greater quantity of 
PRV-PK in the cytosol of infected cells suggests that the major 
functional role(s) of this protein kinase are carried out within 
infected cells rather than within the virion.
However, In vitro, PRV-PK is able to phosphorylate one of the 
major virion structural proteins of molecular weight 112,000 (fig
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3. 19 lane 6>. In vivo, this is the major phosphoproteln in virions 
(fig 3. 18b) and can also be detected in extracts made from cells 
infected with PRV in the presence of C ;3:2P] orthophosphate (fig 3.18a). 
This indicates that the 112kDa protein is a substrate for PRV-PK. In 
previous studies, Stevely et al. , (1985) found that casein kinase II
was able to phosphorylate this viral protein, (a result confirmed 
here, fig 3. 19 lane 2) and they concluded that this cellular protein 
kinase was responsible for the phosphorylation of the major 
phosphoproteln of PRV virions. However, it now appears that the 
112kDa protein can be phosphorylated by two distinct protein kinases. 
This probably occurs at different sites, since these protein kinases 
differ in their substrate specificities (Purves et al. , 1986a; Marin
et al., 1986). Experimental analysis and comparison of the sites 
phosphorylated in vivo and in vitro are needed to determine the 
relative contributions of these two enzymes to the phosphorylation of 
this protein, the function of which still remains to be investigated.
It can thus be concluded that although the location of PRV-PK 
within the virion may be important for the phosphorylation of the 
major phosphoproteln of PRV virions, the abundance of the enzyme 
within the cytosol of infected cells suggests that the major role of 
PRV-PK is played within infected cells, involving the phosphorylation 
of substrate(s), possibly of cellular origin, which are yet to be 
identified.
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